

# Prof. Adriano Lazzarin

## Curriculum vitae



### Informazioni Personali

Unità Operativa Malattie Infettive  
IRCCS Ospedale San Raffaele  
Milano.

### Posizione Corrente:

Professore Onorario di Malattie Infettive dell'Università Vita-Salute San Raffaele, Milano.

Consulente di Malattie Infettive presso IRCCS Ospedale San Raffaele, Milano

Direttore Editoriale del *Journal New Microbiologica* ([www.newmicrobiologica.org](http://www.newmicrobiologica.org))

Direttore Editoriale della Rivista *ReAdfile* ([www.readfiles.it](http://www.readfiles.it))

### Esperienze Professionali

1970-1978: Borsista di Semeiotica Medica ed in seguito di Medicina Interna IV e Malattie Infettive. Università di Milano

1983-1991: Contrattista – Clinica Malattie Infettive  
Ospedale L. Sacco. Università di Milano

1988-1999: Professore Associato di Malattie Infettive. Università degli studi di Milano

1990-1999: Direttore della Scuola di Specializzazione in Malattie Infettive, Università degli studi di Milano

1999-2016: Professore Ordinario di Malattie Infettive, Università Vita-Salute San Raffaele, Milano

2003 Esperto del Consiglio Superiore di Sanità

2000-2016: Direttore della Scuola di Specializzazione in Malattie Infettive e Tropicali, Università Vita-Salute San Raffaele. Milano.

2001-2004: Vice-Direttore Scientifico dell'IRCCS Ospedale San Raffaele Milano.

2005 Delegato Rettorale UniSR alla Commissione bilaterale CRUI-FARMINDUSTRIA.

2002 – 2004 Membro del Collegio per le Politiche e Strategie Ospedaliere IRCCS San Raffaele, Milano.

2011-2015: Presidente del Collegio Nazionale dei Professori Ordinari di Malattie Infettive

1991-2020: Direttore della Divisione di ricerca di Malattie Infettive dell'IRCCS San Raffaele.

Dal 2009 Direttore del Dipartimento Malattie Infettive Istituto Scientifico San Raffaele. (Centro di realizzazione e coordinamento di numerosi studi clinici sperimentali, con utilizzo di terapie sperimentali e implementazione di strategie terapeutiche, in particolare per le infezioni HIV, le epatiti e per la neurovirologia; applicazione di risultati della ricerca nel processo di diagnosi e cura nella pratica clinica).

Nov 2020 ad oggi: Consulente Specialista in Malattie Infettive c/o U.O. di Malattie Infettive dell'IRCCS Ospedale San Raffaele – Sede Turro, Milano.

### **Educazione e Formazione**

Scuola Secondaria Superiore: Liceo Classico. Milano.

1964-1970: MD. Laurea in Medicina e Chirurgia. Università di Milano.

1970-1974: Specializzazione in Endocrinologia e Malattie Metaboliche. Università di Genova.

1974-1979: Specializzazione in Medicina Interna. Università di Milano.

1979-1982: Specializzazione in Malattie Infettive. Università di Milano.

### **Incarichi Professionali svolti**

- Componente della Commissione AIDS – Regione Lombardia.
- Membro della Commissione Nazionale AIDS. Ministero della Salute
- Componente Gruppo di Lavoro per Piano Nazionale di Intervento su HIV/AIDS, Istituto Superiore di Sanità.
- Co-Chair del Gruppo Italiano AIDS e Tumori (GICAT)
- Esperto nel gruppo di assistenza tecnica alla Direzione Regionale Sanità Regione Lombardia.
- Membro del CdA dello Studio I.CO.NA (Italian Cohort Naive Antiretrovirals).
- Membro del direttivo della Società Italiana di Malattie Infettive e Tropicali (SIMIT)
- Presidente del Centro Studi PML, Università Vita-Salute San Raffaele.
- Presidente della Società Italiana di Virologia Medica (SIVIM).
- Presidente del Collegio dei Professori Infettivologi Universitari del MIUR.

## **Riconoscimenti**

2017: Premio alla carriera “*EACS Award for Excellence in HIV Medicine*” da European AIDS Society. 16° EACS - European AIDS Conference (Milan, 25-27 October 2017).

## **Pubblicazioni**

Autore o co-autore di numerosi capitoli di libri e oltre 800 articoli scientifici (H-Index: 84) pubblicati su riviste nazionali ed internazionali peer-reviewed (*New England Journal of Medicine, The Lancet, Blood, Nature, Hepatology, AIDS, Journal of Infectious Diseases, Clinical Infectious Diseases, Science, Annals of Internal Medicine, Annals of Oncology, Journal of Neurology, Journal of Neurovirology, Journal of Acquired Immune Deficiency Syndrome*).

## **Elenco pubblicazioni in allegato.**

Source: PubMed. National Library of Medicine <https://pubmed.ncbi.nlm.nih.gov/?term=Lazzarin+Adriano>

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Milano 12 settembre 2023

Prof. Adriano Lazzarin

## Elenco pubblicazioni prof. Adriano Lazzarin

Source: PubMed. National Library of Medicine <https://pubmed.ncbi.nlm.nih.gov/?term=Lazzarin+Adriano>

1

Cite

### [Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors.](#)

Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, Muccini C, Monti G, De Luca G, Landoni G, Dagna L, Clementi M, Rovere Querini P, Ciceri F, Tresoldi M, **Lazzarin A**, Zangrillo A, Scarpellini P, Castagna A; COVID-BioB study group. *Clin Microbiol Infect.* 2021 Mar;27(3):451-457. doi: 10.1016/j.cmi.2020.10.021. Epub 2020 Oct 24. PMID: 33223114 **Free PMC article.**

2

Cite

### [Bictegravir.](#)

Spagnuolo V, Castagna A, **Lazzarin A**. *Curr Opin HIV AIDS.* 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. PMID: 29746268 Review.

3

Cite

### [Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.](#)

Ogbuagu O, Ruane PJ, Podzamczar D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. *Lancet HIV.* 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. PMID: 34197772 Clinical Trial.

4

Cite

[Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection \(GEMINI-1 and GEMINI-2\): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.](#)

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. *Lancet*. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. PMID: 30420123 Clinical Trial.

5

Cite

[Biobanking for COVID-19 research.](#)

Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, DE Lorenzo R, DI Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, DE Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, DI Napoli D, Bosi E, Tresoldi M, **Lazzarin A**, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, Ciceri F; COVID-BioB Study Group. *Panminerva Med*. 2022 Jun;64(2):244-252. doi: 10.23736/S0031-0808.20.04168-3. Epub 2020 Oct 19. PMID: 33073557

6

Cite

[Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection \(GS-US-380-1489\): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.](#)

Gallant J, **Lazzarin A**, Mills A, Orkin C, Podzamczar D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. *Lancet*. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. PMID: 28867497 Clinical Trial.

7

Cite

[Relapse of Symptomatic Cerebrospinal Fluid HIV Escape.](#)

Ferretti F, De Zan V, Gerevini S, Turrini F, Boeri E, Gianotti N, Hasson H, **Lazzarin A**, Cinque P. *Curr HIV/AIDS Rep*. 2020 Oct;17(5):522-528. doi: 10.1007/s11904-020-00526-x. PMID: 32875516 Review.

8

Cite

[Darunavir for the treatment of HIV infection.](#)

Spagnuolo V, Castagna A, **Lazzarin A**. Expert Opin Pharmacother. 2018 Jul;19(10):1149-1163. doi: 10.1080/14656566.2018.1484901. Epub 2018 Jun 18. PMID: 29913082 Review.

9

Cite

[Raltegravir in treatment naive patients.](#)

Cossarini F, Castagna A, **Lazzarin A**. Eur J Med Res. 2009 Nov 24;14 Suppl 3(Suppl 3):22-9. doi: 10.1186/2047-783x-14-s3-22. PMID: 19959413 **Free PMC article**. Review.

10

Cite

[Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.](#)

Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, Airò P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, **Lazzarin A**, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, Matucci-Cerinic M, Armignacco O, Sarzi-Puttini P. Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-1028. Epub 2017 Nov 28. PMID: 29185961 Review.

11

Cite

[Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?<sup>SEP</sup>](#)

Cattaneo D, Andreoni M, Carosi G, Cauda R, **Lazzarin A**, Rizzardini G. Int J Clin Pharmacol Ther. 2017 May;55(5):381-393. doi: 10.5414/CP202775. PMID: 28211784 Review.

12

Cite

[Enfuvirtide: the first HIV fusion inhibitor.](#)

Lazzarin A. *Expert Opin Pharmacother.* 2005 Mar;6(3):453-64. doi: 10.1517/14656566.6.3.453.PMID: 15794736 Review.

13

Cite

[Management of HIV infection after triple class failure.](#)

Cossarini F, Spagnuolo V, Gianotti N, Carbone A, Lazzarin A, Castagna A. *New Microbiol.* 2013 Jan;36(1):23-39. Epub 2013 Jan 1.PMID: 23435813 **Free article.** Review.

14

Cite

[An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.](#)

Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. *New Microbiol.* 2015 Oct;38(4):443-90.PMID: 26571377 **Free article.** Review.

15

Cite

[HEFFICON: HIV Effectiveness Italian Conference.](#)

Antinori A, Andreoni M, Perno CF, Lazzarin A; HEFFICON Study Group. *New Microbiol.* 2015 Apr;38(2):149-84.PMID: 26013833 **Free article.**

16

Cite

[Central nervous system HIV infection in "less-drug regimen" antiretroviral therapy simplification strategies.](#)

Ferretti F, Gianotti N, **Lazzarin A**, Cinque P. *Semin Neurol.* 2014 Feb;34(1):78-88. doi: 10.1055/s-0034-1372345. Epub 2014 Apr 8. PMID: 24715491 Review.

17

Cite

[Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.](#)

Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, **Lazzarin A**. *New Microbiol.* 2018 Oct;41(4):247-255. PMID: 30604833 **Free article.** Review.

18

Cite

[JC polyomavirus mutants escape antibody-mediated neutralization.](#)

Ray U, Cinque P, Gerevini S, Longo V, **Lazzarin A**, Schippling S, Martin R, Buck CB, Pastrana DV. *Sci Transl Med.* 2015 Sep 23;7(306):306ra151. doi: 10.1126/scitranslmed.aab1720. Epub 2015 Sep 23. PMID: 26400912 **Free PMC article.**

19

Cite

[Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.](#)

Gianotti N, Soria A, **Lazzarin A**. *New Microbiol.* 2007 Apr;30(2):79-88. PMID: 17619250 **Free article.** Review.

20

Cite

[Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.](#)

Benedini S, Terruzzi I, **Lazzarin A**, Luzi L. *BioDrugs.* 2008;22(2):101-12. doi: 10.2165/00063030-200822020-00003. PMID: 18345707 Review.

21



Cite

[Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.](#)

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, **Lazzarin A**; Italian HIV Guidelines Working Group. *New Microbiol.* 2017 Apr;40(2):86-98. PMID: 28513816 **Free article.**

22

Cite

[Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected patients with advanced disease.](#)

Soria A, **Lazzarin A**. *J Acquir Immune Defic Syndr.* 2007 Sep;46 Suppl 1:S19-30. doi: 10.1097/01.qai.0000286598.00313.a6. PMID: 17713422 Review.

23

Cite

[Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.](#)

Clotet B, Raffi F, Cooper D, Delfraissy JF, **Lazzarin A**, Moyle G, Rockstroh J, Soriano V, Schapiro J. *AIDS.* 2004 May 21;18(8):1137-46. doi: 10.1097/00002030-200405210-00007. PMID: 15166529 Review.

24

Cite

[Molecular studies of cerebrospinal fluid in human immunodeficiency virus type 1-associated opportunistic central nervous system diseases--an update.](#)

Cinque P, Bossolasco S, Bestetti A, Sala S, Pierotti C, **Lazzarin A**. *J Neurovirol.* 2002 Dec;8 Suppl 2:122-8. doi: 10.1080/13550280290167957. PMID: 12491163 Review.

25

Cite

[HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy.](#)

Bagaglio S, Uberti-Foppa C, Sagnelli C, Lai A, Hasson H, Salpietro S, Messina E, Morsica G, Zaffina C, Sica A, **Lazzarin A**, Angeletti S, Sagnelli E, Foley B, Ciccozzi M. *Infection*. 2020 Aug;48(4):553-558. doi: 10.1007/s15010-020-01434-3. Epub 2020 May 19. PMID: 32430647

26

Cite

[Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.](#)

Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morsica G, Regalia E, Bagaglio S, **Lazzarin A**, Uberti-Foppa C, Mazzaferro V. *J Hepatol*. 2017 Aug;67(2):415-417. doi: 10.1016/j.jhep.2017.03.032. Epub 2017 Apr 12. PMID: 28411040 No abstract available.

27

Cite

[Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing.](#)

Raccagni AR, Soldini L, Nozza S, Negri S, Vidoni GM, Ferrara F, Parisi MR, Passeri L, Siracusano G, Raddato C, Castagna A, Schlusnus K, **Lazzarin A**. *New Microbiol*. 2022 Dec;45(4):320-323. PMID: 36538296 **Free article.**

28

Cite

[Exercise ECG for coronary artery disease screening in people living with HIV.](#)

Muccini C, Galli L, Poli A, Godino C, Gianotti N, Nozza S, Giusti MC, **Lazzarin A**, Margonato A, Castagna A, Spagnuolo V. *AIDS*. 2021 May 1;35(6):933-938. doi: 10.1097/QAD.0000000000002828. PMID: 33534202

29

Cite

[Susac's syndrome as HIV-associated immune reconstitution inflammatory syndrome.](#)

Ferretti F, Gerevini S, Colombo B, Testa M, Guffanti M, Franciotta D, Bernardi G, **Lazzarin A**, Cinque P. *AIDS Res Ther.* 2013 Sep 3;10(1):22. doi: 10.1186/1742-6405-10-22. PMID: 24004690 **Free PMC article.**

30

Cite

[Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.](#)

Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, Rovelli C, **Lazzarin A**, Castagna A, Tambussi G. *J Antimicrob Chemother.* 2017 Feb;72(2):632-633. doi: 10.1093/jac/dkw439. Epub 2016 Oct 17. PMID: 27798217 No abstract available.

31

Cite

[Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.](#)

Sax PE, Arribas JR, Orkin C, **Lazzarin A**, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D; GS-US-380-1489 and GS-US-380-1490 study investigators. *EClinicalMedicine.* 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May. PMID: 37200995 **Free PMC article.**

32

Cite

[The Less Drugs Regimens \(LDRs\) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.](#)

Scientific Coordination Committee; Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, **Lazzarin A**; Rapporteur Committee; Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. *New Microbiol.* 2012 Jul;35(3):259-77. Epub 2012 Jun 30. PMID: 22842596 **Free article.** No abstract available.

33

Cite

[Coronaviridae and SARS-associated coronavirus strain HSR1.](#)

Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, **Lazzarin A**, Bordignon C, Poli G, Clementi M. *Emerg Infect Dis.* 2004 Mar;10(3):413-8. doi: 10.3201/eid1003.030683.PMID: 15109406 **Free PMC article.**

34

Cite

[Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.](#)

Fätkenheuer G, Nelson M, **Lazzarin A**, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. *N Engl J Med.* 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.PMID: 18832245 **Free article.**

35

Cite

[Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.](#)

Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, **Lazzarin A**, Odesloo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM. *J Int Assoc Physicians AIDS Care (Chic).* 2004 Jul-Sep;3(3):92-8. doi: 10.1177/154510970400300304.PMID: 15573713 Review.

36

Cite

[Access denied? The status of co-receptor inhibition to counter HIV entry.](#)

Biswas P, Tambussi G, **Lazzarin A**. *Expert Opin Pharmacother.* 2007 May;8(7):923-33. doi: 10.1517/14656566.8.7.923.PMID: 17472538 Review.

37

Cite

[Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.](#)

Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, Rovelli C, **Lazzarin A**, Castagna A, Tambussi G.J Antimicrob Chemother. 2017 May 1;72(5):1549-1550. doi: 10.1093/jac/dkx073.PMID: 28333303 No abstract available.

38

Cite

[The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.](#)

Cinque P, Bossolasco S, Brambilla AM, Boschini A, Mussini C, Pierotti C, Campi A, Casari S, Bertelli D, Mena M, **Lazzarin A**.J Neurovirol. 2003;9 Suppl 1:73-80. doi: 10.1080/13550280390195351.PMID: 12709876 Review.

39

Cite

[A Mobile Application for Exercise Intervention in People Living with HIV.](#)

Bonato M, Turrini F, DE Zan V, Meloni A, Plebani M, Brambilla E, Giordani A, Vitobello C, Caccia R, Piacentini MF, LA Torre A, **Lazzarin A**, Merati G, Galli L, Cinque P.Med Sci Sports Exerc. 2020 Feb;52(2):425-433. doi: 10.1249/MSS.0000000000002125.PMID: 31415448 Clinical Trial.

40

Cite

[Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV.](#)

Bonato M, Galli L, Bossolasco S, Bertocchi C, Balconi G, Borderi M, Viale P, Pavei G, Merati G, La Torre A, **Lazzarin A**, Banfi G, Cinque P.J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1613-1616. doi: 10.1002/jcsm.12824. Epub 2021 Oct 1.PMID: 34596347 **Free PMC article**. No abstract available.

41

Cite

[Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy.](#)

Sagnelli C, Uberti-Foppa C, Bagaglio S, Cella E, Scolamacchia V, Hasson H, Salpietro S, Messina E, Morsica G, Angeletti S, Ciccozzi M, **Lazzarin A**, Sagnelli E. *Epidemiol Infect.* 2020 Feb 5;148:e19. doi: 10.1017/S0950268819002012. PMID: 32019634 **Free PMC article.**

42

Cite

[Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection.](#)

Rinaldi F, Rolla S, Galli L, Poli A, Muccini C, Mastrangelo A, Tavano C, **Lazzarin A**, Bartoloni A, Castagna A. *New Microbiol.* 2020 Apr;43(2):55-57. Epub 2020 Apr 19. PMID: 32310296 **Free article.**

43

Cite

[Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy.](#)

Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, Conte C, De Lorenzo R, Poli A, Ambrosio A, Signorelli C, Bossi E, Fazio M, Tresoldi C, Colombo S, Monti G, Fominskiy E, Franchini S, Spessot M, Martinenghi C, Carlucci M, Beretta L, Scandroglio AM, Clementi M, Locatelli M, Tresoldi M, Scarpellini P, Martino G, Bosi E, Dagna L, **Lazzarin A**, Landoni G, Zangrillo A. *Clin Immunol.* 2020 Aug;217:108509. doi: 10.1016/j.clim.2020.108509. Epub 2020 Jun 12. PMID: 32535188 **Free PMC article.** Clinical Trial.

44

Cite

[Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression.](#)

Dell'Acqua R, Galli L, Poli A, Mastrangelo A, Guffanti M, Tadini P, Zandona D, Danise A, Gianotti N, **Lazzarin A**, Castagna A, Nozza S. *AIDS.* 2019 Nov 1;33(13):1987-1994. doi: 10.1097/QAD.0000000000002307. PMID: 31306174

45

Cite

[stARTing cART now! HIV treatment Italian Guidelines Update Dec. 2014.](#)

**Lazzarin A**, Antinori A, Marcotullio S. *New Microbiol.* 2015 Jul;38(3):297-8. PMID: 26415241 **Free article.** No abstract available.

46

Cite

[An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.](#)

Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, **Lazzarin A**, Castagna A. *Infect Dis (Lond).* 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11. PMID: 28891371 No abstract available.

47

Cite

[Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.](#)

Bagaglio S, Messina E, Hasson H, Merli M, Andolina A, **Lazzarin A**, Uberti-Foppa C, Morsica G. *New Microbiol.* 2017 Jan;40(1):53-55. Epub 2017 Jan 5. PMID: 28072886 **Free article.**

48

Cite

[Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.](#)

Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, **Lazzarin A**, Castagna A. *Drug Des Devel Ther.* 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. PMID: 35783200 **Free PMC article.**

49

Cite

[Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.](#)

Saracino A, Gianotti N, Marangi M, Cibelli DC, Galli A, Punzi G, Monno L, **Lazzarin A**, Angarano G; Mutations, Salvage Study Group. *J Med Virol.* 2008 Oct;80(10):1695-706. doi: 10.1002/jmv.21261.PMID: 18712823

50

Cite

[Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.](#)

Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C, **Lazzarin A**, Castagna A. *AIDS.* 2012 Sep 10;26(14):1837-40. doi: 10.1097/QAD.0b013e32835705dd.PMID: 22739393

51

Cite

[Candidemia in Coronavirus Disease 2019 \(COVID-19\) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls.](#)

Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Li Voti R, Muccini C, Ripa M; COVID-BioB Study Group. *Clin Infect Dis.* 2021 Nov 2;73(9):e2838-e2839. doi: 10.1093/cid/ciaa1594.PMID: 33124650 **Free PMC article.** No abstract available.

52

Cite

[Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy.](#)

Ferretti F, Bestetti A, Yiannoutsos CT, Musick BS, Gerevini S, Passeri L, Bossolasco S, Boschini A, Franciotta D, **Lazzarin A**, Cinque P. *Clin Infect Dis.* 2018 Jun 18;67(1):65-72. doi: 10.1093/cid/ciy030.PMID: 29346632

53

Cite



[Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.](#)

Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, Cossarini F, Vinci C, Carini E, **Lazzarin A**, Castagna A. *BMC Infect Dis.* 2017 Jan 7;17(1):43. doi: 10.1186/s12879-016-2099-5. PMID: 28061820 **Free PMC article.**

54

Cite

[Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.](#)

Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. *Open Forum Infect Dis.* 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. PMID: 33241063 **Free PMC article.**

55

Cite

[Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.](#)

Castagna A, Galli L, Gianotti N, Torti C, Antinori A, Maserati R, d'Arminio Monforte A, Quiros-Roldan E, Salpietro S, **Lazzarin A**. *New Microbiol.* 2013 Jul;36(3):239-49. Epub 2013 Jun 30. PMID: 23912865 **Free article.**

56

Cite

[Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.](#)

Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A, Antonelli G, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bonn I, Bruzzone B, Callegaro AP, Cammarota R, Canducci F, Ceccherini-Silberstein F, Clementi M, Monforte AD, De Luca A, Di Biagio A, Di Gianbenedetto S, Di Perri G, Di Pietro M, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori A, Leoncini F, Maggiolo F, Maserati R, Mazzotta F, Micheli V, Meini G, Monno L, Mussini C, Nozza S, Paolucci S, Parisi S, Pecorari M, Pizzi D, Quirino T, Re MC, Rizzardini G, Santangelo R, Soria A, Stazi F, Sterrantino G, Turriziani O, Viscoli C, Vullo V, **Lazzarin A**, Perno CF; OSCAR Study Group. *New Microbiol.* 2010 Jul;33(3):195-206. PMID: 20954437 **Free article.**

57

Cite

[Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.](#)

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, **Lazzarin A**, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M. *New Microbiol.* 2018 Apr;41(2):112-117. PMID: 29806690 **Free article.**

58

Cite

[Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.](#)

Gianotti N, Galli L, Poli A, Torre LD, Vinci C, Carini E, Galli A, Nozza S, Spagnuolo V, Muccini C, **Lazzarin A**, Castagna A. *AIDS.* 2021 Jul 15;35(9):1513-1516. doi: 10.1097/QAD.0000000000002908. PMID: 33831909 Clinical Trial.

59

Cite

[Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.](#)

Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, **Lazzarin A**, Clementi M. *J Antimicrob Chemother.* 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7. PMID: 20056687

60

Cite

[A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.](#)

Spagnuolo V, Galli L, Poli A, Bigoloni A, Fumagalli L, Gianotti N, Nozza S, Ferrari D, Locatelli M, **Lazzarin A**, Castagna A. *Drug Des Devel Ther.* 2019 Jan 24;13:477-479. doi: 10.2147/DDDT.S192124. eCollection 2019. PMID: 30774311 **Free PMC article.** Clinical Trial. No abstract available.

61

Cite

[Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial \(2pm Study\).](#)

Gianotti N, Galli L, Maserati R, Sighinolfi L, Ripamonti D, Palvarini L, Lo Caputo S, Focà E, Celesia BM, Baldelli F, Sterrantino G, **Lazzarin A**. *New Microbiol.* 2016 Oct;39(4):290-294. Epub 2016 Aug 23. PMID: 27551725 **Free article.** Clinical Trial.

62

Cite

[Genotypic resistance tests for the clinical management of patients with primary HIV infection.](#)

Narciso P, **Lazzarin A**. *Scand J Infect Dis Suppl.* 2003;106:66-70. PMID: 15000588 Review.

63

Cite

[Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.](#)

Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, Guffanti M, Gianotti N, Bigoloni A, **Lazzarin A**, Castagna A. *Eur J Epidemiol.* 2012 Aug;27(8):657-65. doi: 10.1007/s10654-012-9707-5. Epub 2012 Jun 22. PMID: 22722952

64

Cite

[Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.](#)

Nozza S, Galli L, Bigoloni A, Gianotti N, Spagnuolo V, Carbone A, Chiappetta S, Ripa M, Tambussi G, **Lazzarin A**, Castagna A. *New Microbiol.* 2014 Apr;37(2):145-51. Epub 2014 Apr 1. PMID: 24858641 **Free article.** Clinical Trial.

65

Cite

[Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.](#)

Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, **Lazzarin A**; Italian HIV Guidelines Working Group. *New Microbiol.* 2011 Apr;34(2):109-46. Epub 2011 Apr 30. PMID: 21617825 **Free article.** No abstract available.

66

Cite

[Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.](#)

Nelson M, Rubio R, **Lazzarin A**, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S. *J Interferon Cytokine Res.* 2017 Mar;37(3):103-111. doi: 10.1089/jir.2016.0082. Epub 2017 Feb 17. PMID: 28282271 *Clinical Trial.*

67

Cite

[Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.](#)

Carbone A, Galli L, Bigoloni A, Bossolasco S, Guffanti M, Maillard M, Carini E, Salpietro S, Spagnuolo V, Gianotti N, **Lazzarin A**, Castagna A. *J Int AIDS Soc.* 2014 Nov 2;17(4 Suppl 3):19811. doi: 10.7448/IAS.17.4.19811. eCollection 2014. PMID: 25397555 **Free PMC article.**

68

Cite

[No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.](#)

Gianotti N, Galli L, Sampaolo M, Lolatto R, Carini E, Annicchiarico G, Baglivi A, Della Torre L, **Lazzarin A**, Castagna A. *New Microbiol.* 2023 May;46(2):154-160. PMID: 37247236 **Free article.**

69

Cite

[Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015.](#)

Antinori A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, **Lazzarin A**; Italian HIV Guidelines Working Group. *New Microbiol.* 2016 Apr;39(2):93-109. PMID: 27196547 **Free article.** No abstract available.

70

Cite

[Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.](#)

Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, **Lazzarin A**, Castagna A. *Int J Cancer.* 2012 Jun 15;130(12):2990-6. doi: 10.1002/ijc.26332. Epub 2011 Aug 30. PMID: 21796633 **Free article.**

71

Cite

[Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.](#)

Gianotti N, Muccini C, Galli L, Poli A, Spagnuolo V, Andolina A, Galizzi N, Ripa M, Messina E, Piatti PM, **Lazzarin A**, Castagna A. *J Med Virol.* 2019 Nov;91(11):1937-1943. doi: 10.1002/jmv.25541. Epub 2019 Jul 16. PMID: 31286527

72

Cite

[Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.](#)

Merli M, Galli L, Castagna A, Salpietro S, Gianotti N, Messina E, Poli A, Morsica G, Bagaglio S, Cernuschi M, Bigoloni A, Uberti-Foppa C, **Lazzarin A**, Hasson H. *New Microbiol.* 2016 Apr;39(2):110-3. PMID: 27196548 **Free article.**

73

Cite

[Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases.](#)

Sagnelli C, Uberti-Foppa C, Galli L, Pasquale G, Coppola N, Albarello L, Masiello A, Doglioni C, **Lazzarin A**, Sagnelli E. *J Acquir Immune Defic Syndr.* 2010 May 1;54(1):107-8. doi: 10.1097/QAI.0b013e3181cf4d8b.PMID: 20418725 No abstract available.

74

Cite

[Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.](#)

Castagna A, Ferrara M, Galli L, Comi L, Sterrantino G, Cenderello G, Zaccarelli M, Focà E, Roncadori A, **Lazzarin A**; PRESTIGIO Study Group. *J Antimicrob Chemother.* 2018 Jan 1;73(1):177-182. doi: 10.1093/jac/dkx371.PMID: 29077927

75

Cite

[Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.](#)

Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Florida M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, **Lazzarin A**; Italian HIV Guidelines Working Group. *New Microbiol.* 2012 Apr;35(2):113-59. Epub 2012 Mar 31.PMID: 22707127 **Free article.** No abstract available.

76

Cite

[Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.](#)

Colella E, Cattaneo D, Galli L, Baldelli S, Clementi E, Galli M, **Lazzarin A**, Castagna A, Rusconi S, Spagnuolo V. *New Microbiol.* 2018 Apr;41(2):106-111. Epub 2018 Mar 2.PMID: 29498742 **Free article.**

77

Cite

[Sequencing antiretroviral drugs for long-lasting suppression of HIV replication.](#)

Gianotti N, **Lazzarin A**. *New Microbiol.* 2005 Oct;28(4):281-97. PMID: 16386013 Review.

78

Cite

[Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy.](#)

Galli L, Spagnuolo V, Salpietro S, Gianotti N, Cossarini F, **Lazzarin A**, Castagna A. *Antivir Ther.* 2012;17(3):447-58. doi: 10.3851/IMP1984. Epub 2011 Nov 18. PMID: 22293436

79

Cite

[Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.](#)

Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F, Salpietro S, Galli A, Della Torre L, Tambussi G, **Lazzarin A**, Castagna A. *J Acquir Immune Defic Syndr.* 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4. PMID: 21350358 Clinical Trial. No abstract available.

80

Cite

[Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients.](#)

Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, **Lazzarin A**, Sagnelli E, Rossi F. *PLoS One.* 2017 Jul 31;12(7):e0181890. doi: 10.1371/journal.pone.0181890. eCollection 2017. PMID: 28759568 **Free PMC article.**

81

Cite

[Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.](#)

Stellbrink HJ, Reynes J, **Lazzarin A**, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S; SPRING-1 Team. *AIDS*. 2013 Jul 17;27(11):1771-8. doi: 10.1097/QAD.0b013e3283612419.PMID: 23807273 **Free PMC article**. Clinical Trial.

82

Cite

[Predictors of lack of serological response to syphilis treatment in HIV-infected subjects.](#)

Spagnuolo V, Poli A, Galli L, Cernuschi M, Nozza S, Maillard M, Gianotti N, Hasson H, Bossolasco S, **Lazzarin A**, Castagna A. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19654. doi: 10.7448/IAS.17.4.19654. eCollection 2014.PMID: 25394158 **Free PMC article**.

83

Cite

[Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.](#)

Belmonti S, Lombardi F, Quiros-Roldan E, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group. *J Antimicrob Chemother*. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125.PMID: 29788156 Clinical Trial.

84

Cite

[Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.](#)

Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Panicia G, **Lazzarin A**, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. *Vaccine*. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7.PMID: 19208456 Clinical Trial.

85

Cite



[Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.](#)

Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. *Dig Liver Dis.* 2010 Feb;42(2):81-91. doi: 10.1016/j.dld.2009.08.001. Epub 2009 Sep 11. PMID: 19748329

86

Cite

[Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.](#)

Gianotti N, Guffanti M, Galli L, Margonato A, Chiaravalli G, Bigoloni A, **Lazzarin A**, Castagna A. *AIDS.* 2007 Jul 31;21(12):1648-51. doi: 10.1097/QAD.0b013e32826fbc6a. PMID: 17630564

87

Cite

Share

[Improvement of CXCR3 ligand CXCL11/I-TAC measurement in human plasma and serum.](#)

Cremasco V, Mantelli B, **Lazzarin A**, Biswas P. *New Microbiol.* 2009 Jan;32(1):125-8. PMID: 19382679 **Free article.**

88

Cite

[Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.](#)

Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, **Lazzarin A**, Castagna A. *PLoS One.* 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. eCollection 2017. PMID: 28763473 **Free PMC article.**

89

Cite

[ABC of AIDS: treatment of infections and antiviral agents.](#)

Esposito R, **Lazzarin A**, Orlando G, Galli M, Foppa CU. Br Med J (Clin Res Ed). 1987 Sep 12;295(6599):668-9. doi: 10.1136/bmj.295.6599.668-b.PMID: 3117281 **Free PMC article**. Review. No abstract available.

90

Cite

[Point-of-care testing for HCV infection: recent advances and implications for alternative screening.](#)

Parisi MR, Soldini L, Vidoni G, Mabellini C, Belloni T, Brignolo L, Negri S, Schlusnus K, Dorigatti F, **Lazzarin A**. New Microbiol. 2014 Oct;37(4):449-57. Epub 2014 Oct 1. PMID: 25387283 **Free article**.

91

Cite

[Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.](#)

Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R, Clumeck N, Walmsley S, **Lazzarin A**, Mukwaya G, Saag M, van Der Ryst E. AIDS. 2014 Mar 13;28(5):717-25. doi: 10.1097/QAD.000000000000131. PMID: 24983542 **Free PMC article**. Clinical Trial.

92

Cite

[The preventive phase I trial with the HIV-1 Tat-based vaccine.](#)

Ensoli B, Fiorelli V, Ensoli F, **Lazzarin A**, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29. PMID: 19879233 Clinical Trial.

93

Cite

[Early diagnosis and retention in care of HIV-infected patients through rapid salivary testing: a test-and-treat fast track pilot study.](#)

Parisi MR, Soldini L, Negri S, Vidoni GM, Gianotti N, Nozza S, Schlusnus K, Dorigatti F, **Lazzarin A**. *New Microbiol.* 2016 Jan;39(1):57-60. PMID: 26922986 **Free article.**

94

Cite

[The use of circulating cathodic antigen rapid test and serology for diagnosis of active \*Schistosoma mansoni\* infection in migrants in Italy, a non-endemic country: a cross sectional study.](#)

Infurnari L, Galli L, Bigoloni A, Carbone A, Chiappetta S, Sala A, Ceserani N, **Lazzarin A**, Castagna A, Gaiera/G. *Mem Inst Oswaldo Cruz.* 2017 Jun;112(6):452-455. doi: 10.1590/0074-02760160355. PMID: 28591406 **Free PMC article.**

95

Cite

[Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death.](#)

Fontdevila MC, Cozzi-Lepri A, Phillips A, Julian MN, Bickel M, Sedlacek D, Kronborg G, **Lazzarin A**, Zilmer K, Clotet B, Lundgren JD, Paredes R. *J Int AIDS Soc.* 2014 Nov 2;17(4 Suppl 3):19685. doi: 10.7448/IAS.17.4.19685. eCollection 2014. PMID: 25397435 **Free PMC article.**

96

Cite

[Early diagnosis and retention in care of HIV-infected patients through rapid salivary testing: a test-and-treat fast track pilot study.](#)

Parisi MR, Soldini L, Negri S, Vidoni GM, Gianotti N, Nozza S, Schlusnus K, Dorigatti F, **Lazzarin A**. *New Microbiol.* 2015 Oct 20;38(4). Online ahead of print. PMID: 26485021 **Free article.**

97

Cite

[Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.](#)

Caumo A, Guffanti M, Perseghin G, Galli L, **Lazzarin A**, Luzi L, Castagna A. *AIDS*. 2007 Nov 12;21(17):2366-7. doi: 10.1097/QAD.0b013e3282f20a62. PMID: 18090297 No abstract available.

98

Cite

[Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.](#)

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, **Lazzarin A**, Castagna A; MODAt Study Group. *J Antimicrob Chemother*. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5. PMID: 26945711 Clinical Trial.

99

Cite

[Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus \(HCV\)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.](#)

Merli M, Messina E, Salpietro S, **Lazzarin A**, Uberti-Foppa C, Hasson H. *Clin Infect Dis*. 2016 Feb 15;62(4):527-8. doi: 10.1093/cid/civ902. Epub 2015 Oct 27. PMID: 26508514 No abstract available.

100

Cite

[Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.](#)

Scutari R, Galli L, Alteri C, Poli A, Piermatteo L, Bigoloni A, Perno CF, **Lazzarin A**, Ceccherini-Silberstein F, Castagna A, Santoro MM, Gianotti N. *Int J Antimicrob Agents*. 2023 May;61(5):106771. doi: 10.1016/j.ijantimicag.2023.106771. Epub 2023 Mar 3. PMID: 36870403 Clinical Trial.

101

Cite

[An epidemiologic study to determine the prevalence of the HLA-B\\*5701 allele among HIV-positive patients in Europe.](#)

Orkin C, Wang J, Bergin C, Molina JM, **Lazzarin A**, Cavassini M, Esser S, Gómez Sirvent JL, Pearce H. *Pharmacogenet Genomics*. 2010 May;20(5):307-14. doi: 10.1097/FPC.0b013e3283390666.PMID: 20375757

102

Cite

[Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014.](#)

Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, **Lazzarin A**; Italian HIV Guidelines Working Group. *New Microbiol*. 2015 Jul;38(3):299-328.PMID: 26422838 **Free article**. No abstract available.

103

Cite

[Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.](#)

Marcotullio S, Ammassari A, Andreoni M, Antinori A, Bonora S, d'Arminio Monforte A, Di Perri G, Galli M, Gervasoni C, Iardino R, Ippolito G, Lo Caputo S, Nozza S, Perno CF, Rizzardini G, **Lazzarin A**. *New Microbiol*. 2014 Apr;37(2):163-75. Epub 2014 Apr 1.PMID: 24858643 **Free article**.

104

Cite

[The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.](#)

Ensoli B, Fiorelli V, Ensoli F, **Lazzarin A**, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E. *AIDS*. 2008 Oct 18;22(16):2207-9. doi: 10.1097/QAD.0b013e32831392d4.PMID: 18832884 Clinical Trial.

105

Cite

[Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.](#)

Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. *J Antimicrob Chemother.* 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479.PMID: 31754703 Clinical Trial.

106

Cite

[HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy.](#)

Croce D, **Lazzarin A**, Rizzardini G, Gianotti N, Scolari F, Foglia E, Garagiola E, Ricci E, Bini T, Quirino T, Viganò P, Re T, D'Arminio Monforte A, Bonfanti P. *PLoS One.* 2016 Dec 28;11(12):e0168399. doi: 10.1371/journal.pone.0168399. eCollection 2016.PMID: 28030621 **Free PMC article.**

107

Cite

[HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study \(KaMon study\).](#)

Hasson H, Galli L, Gallotta G, Neri V, Blanc P, D'Annunzio M, Morsica G, Sollima S, Merli M, **Lazzarin A**, Uberti-Foppa C. *New Microbiol.* 2012 Oct;35(4):469-74. Epub 2012 Oct 1.PMID: 23109014 **Free article.** Clinical Trial.

108

Cite

[Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV.](#)

Spagnuolo V, Poli A, Galli L, Nozza S, Bossolasco S, Cernuschi M, Maillard M, Hasson H, Gianotti N, Guffanti M, **Lazzarin A**, Castagna A. *Open Forum Infect Dis.* 2018 Nov 30;6(1):ofy324. doi: 10.1093/ofid/ofy324. eCollection 2019 Jan.PMID: 30631790 **Free PMC article.**

109

Cite

[Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression.](#)

Muccini C, Galli L, Poli A, Carbone A, Maillard M, Giusti MC, Spagnuolo V, Bigoloni A, Guffanti M, Gianotti N, **Lazzarin A**, Castagna A.J *Acquir Immune Defic Syndr*. 2018 Dec 15;79(5):617-623. doi: 10.1097/QAI.0000000000001854.PMID: 30204718

110

Cite

[Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population.](#)

Tecco S, Parisi MR, Gastaldi G, Polizzi E, D'Amicantonio T, Zilocchi I, Gardini I, Gherlone EF, **Lazzarin A**, Cappare P.*New Microbiol*. 2019 Jul;42(3):133-138. Epub 2019 Jun 3.PMID: 31157397 **Free article.**

111

Cite

[Durability of lopinavir/ritonavir monotherapy in individuals with viral load  \$\leq 50\$  copies/ml in an observational setting.](#)

d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, **Lazzarin A**, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort.*Antivir Ther*. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13.PMID: 24036891

112

Cite

[Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort.](#)

Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group.*Dig Liver Dis*. 2021 Dec;53(12):1603-1609. doi: 10.1016/j.dld.2021.03.020. Epub 2021 Apr 21.PMID: 33893040 **Free article.**

113

Cite

[Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.](#)

Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, **Lazzarin A**, Castagna A, Mancusi D, Termini R. PLoS One. 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018. PMID: 29451870 **Free PMC article.**

114

Cite

[A step ahead on the HIV collaboratory.](#)

Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, **Lazzarin A**, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. Science. 2009 Jun 5;324(5932):1264-5. doi: 10.1126/science.324\_1264b. PMID: 19498149 No abstract available.

115

Cite

[Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.](#)

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. PMID: 29808463

116

Cite

[Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk.](#)

Galli L, Rubinacci A, Cocorullo D, Salpietro S, Spagnuolo V, Gianotti N, Bigoloni A, Vinci C, Mignogna G, Sirtori M, **Lazzarin A**, Castagna A. Clin Nutr. 2014 Apr;33(2):363-6. doi: 10.1016/j.clnu.2013.07.004. Epub 2013 Jul 12. PMID: 23891159



117

Cite

[Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.](#)

Bagaglio S, Uberti-Foppa C, Di Serio C, Trentini F, Andolina A, Hasson H, Messina E, Merli M, Porrino L, **Lazzarin A**, Morsica G. *Medicine (Baltimore)*. 2015 Oct;94(43):e1876. doi: 10.1097/MD.0000000000001876.PMID: 26512601 **Free PMC article**. Clinical Trial.

118

Cite

[Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.](#)

De Bona A, Galli L, Gallotta G, Guzzo A, Alagna L, **Lazzarin A**, Uberti-Foppa C. *New Microbiol*. 2007 Jul;30(3):259-64.PMID: 17802905 **Free article**.

119

Cite

[Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.](#)

Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, **Lazzarin A**; MODAt Study Group. *AIDS*. 2014 Sep 24;28(15):2269-79. doi: 10.1097/QAD.0000000000000407.PMID: 25058680 **Free article**. Clinical Trial.

120

Cite

[Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone.](#)

Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M, Terreni MR, **Lazzarin A**, Crippa F. *J Clin Oncol*. 2012 Apr 1;30(10):e119-21. doi: 10.1200/JCO.2011.39.9642. Epub 2012 Feb 21.PMID: 22355047 No abstract available.

121

Cite

[Expression of CD4 on human peripheral blood neutrophils.](#)

Biswas P, Mantelli B, Sica A, Malnati M, Panzeri C, Sacconi A, Hasson H, Vecchi A, Saniabadi A, Lusso P, **Lazzarin A**, Beretta A. *Blood*. 2003 Jun 1;101(11):4452-6. doi: 10.1182/blood-2002-10-3056. Epub 2003 Jan 16. PMID: 12531788 **Free article.**

122

Cite

[Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection.](#)

Guernon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, Vicenzi E, Morsica G, Tinelli M, Zanone Poma B, Goujard C, Potard V, Gotch FM, Casoli C, Cossarizza A, Macciardi F, Debré P, Delfraissy JF, Galli M, Autran B, Costagliola D, Poli G, Theodorou I, Riva A; GISHEAL Consortium. *J Infect Dis*. 2012 Mar 1;205(5):718-24. doi: 10.1093/infdis/jir833. Epub 2012 Jan 11. PMID: 22238471

123

Cite

[Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?](#)

Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group. *AIDS Rev*. 2017 Oct-Dec;19(3):119-133. PMID: 28926559

124

Cite

[Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic.](#)

Parisi MR, Tecco S, Gastaldi G, Polizzi E, D'Amicantonio T, Negri S, Gardini I, Schlusnus K, Gherlone E, Cappare P, **Lazzarin A**. *New Microbiol*. 2017 Oct;40(4):242-245. Epub 2017 Aug 21. PMID: 28825443 **Free article.**

125

Cite

[Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression.](#)

Crotti A, Lusic M, Lupo R, Lievens PM, Liboi E, Della Chiara G, Tinelli M, **Lazzarin A**, Patterson BK, Giacca M, Bovolenta C, Poli G. *Blood*. 2007 Jun 15;109(12):5380-9. doi: 10.1182/blood-2006-08-042556. Epub 2007 Mar 1. PMID: 17332243 **Free article.**

126

Cite

[Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA \(APACHE study\).](#)

Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, **Lazzarin A**. *J Antimicrob Chemother*. 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. PMID: 31225610

127

Cite

[Raltegravir with optimized background therapy for resistant HIV-1 infection.](#)

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, **Lazzarin A**, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Tepler H; BENCHMRK Study Teams. *N Engl J Med*. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975. PMID: 18650512 **Free article.** Clinical Trial.

128

Cite

[Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.](#)

Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Palù G, Clementi M, Zazzi M, Andreoni M, Antinori A, **Lazzarin A**, Ceccherini-Silberstein F, Perno CF; OSCAR study group. *Antivir Ther.* 2011;16(7):1035-45. doi: 10.3851/IMP1862.PMID: 22024519

129

Cite

[Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.](#)

DeJesus E, Rockstroh JK, Lennox JL, Saag MS, **Lazzarin A**, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators. *HIV Clin Trials.* 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228.PMID: 22849964 Clinical Trial.

130

Cite

[Immunomodulatory effects of bovine colostrum in human peripheral blood mononuclear cells.](#)

Biswas P, Vecchi A, Mantegani P, Mantelli B, Fortis C, **Lazzarin A**. *New Microbiol.* 2007 Oct;30(4):447-54.PMID: 18080681 **Free article.**

131

Cite

[Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.](#)

Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, **Lazzarin A**, Castagna A, Gianotti N. *Int J Antimicrob Agents.* 2020 Mar;55(3):105893. doi: 10.1016/j.ijantimicag.2020.105893. Epub 2020 Jan 9.PMID: 31926287

132

Cite

[Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.](#)

Molina JM, Clotet B, van Lunzen J, **Lazzarin A**, Cavassini M, Henry K, Kulagin V, Givens N, Brennan C, de Oliveira CF. *J Int AIDS Soc.* 2014 Nov 2;17(4 Suppl 3):19490. doi: 10.7448/IAS.17.4.19490. eCollection 2014. PMID: 25393999 **Free PMC article.**

133

Cite

[Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.](#)

Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, **Lazzarin A**, Castagna A. *Int J Antimicrob Agents.* 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13. PMID: 30009958

134

Cite

[Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets.](#)

Pogliaghi M, Ripa M, Pensieroso S, Tolazzi M, Chiappetta S, Nozza S, **Lazzarin A**, Tambussi G, Scarlatti G. *PLoS One.* 2015 Oct 16;10(10):e0140435. doi: 10.1371/journal.pone.0140435. eCollection 2015. PMID: 26474181 **Free PMC article.** Clinical Trial.

135

Cite

[Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.](#)

Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S, Gianotti N, Bigoloni A, Torre LD, Tambussi G, **Lazzarin A**, Castagna A. *AIDS.* 2010 Mar 27;24(6):924-8. doi: 10.1097/QAD.0b013e3283372d76. PMID: 20154578

136

Cite

[SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic.](#)

Canetti D, Dell'Acqua R, Riccardi N, Della Torre L, Bigoloni A, Muccini C, Bruzzesi E, Ranzenigo M, Chiurlo M, Racca S, Galli C, Castagna A, Tambussi G, **Lazzarin A**. *New Microbiol.* 2020 Oct;43(4):161-165. Epub 2020 Oct 31. PMID: 33135083 **Free article.**

137

Cite

[Maraviroc for previously treated patients with R5 HIV-1 infection.](#)

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. *N Engl J Med.* 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152. PMID: 18832244 **Free PMC article.** Clinical Trial.

138

Cite

[Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.](#)

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, **Lazzarin A**, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Tepler H, Nguyen BY; BENCHMRK Study Teams. *N Engl J Med.* 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978. PMID: 18650513 **Free article.** Clinical Trial.

139

Cite

[Disseminated \*Rhodococcus equi\* infection in HIV infection despite highly active antiretroviral therapy.](#)

Ferretti F, Boschini A, Iabichino C, Gerevini S, De Nardi P, Guffanti M, Balconi G, **Lazzarin A**, Cinque P. *BMC Infect Dis.* 2011 Dec 14;11:343. doi: 10.1186/1471-2334-11-343. PMID: 22168333 **Free PMC article.**

140

Cite

[Long-term \(96-week\) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.](#)

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group. *HIV Med.* 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13. PMID: 19682100 **Free article.** Clinical Trial.

141

Cite

[Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.](#)

Lennox JL, Dejesus E, Berger DS, **Lazzarin A**, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Tepler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. *J Acquir Immune Defic Syndr.* 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. PMID: 20404738 **Free PMC article.** Clinical Trial.

142

Cite

[Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.](#)

Gianotti N, Poli A, Nozza S, Galli L, Galizzi N, Ripa M, Merli M, Carbone A, Spagnuolo V, **Lazzarin A**, Castagna A. *BMC Infect Dis.* 2017 Nov 16;17(1):723. doi: 10.1186/s12879-017-2831-9. PMID: 29145807 **Free PMC article.**

143

Cite

[Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin \(16 weeks and 12 weeks\) vs sofosbuvir + ribavirin \(16 weeks and 24 weeks\) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.](#)

Restelli U, Alberti A, **Lazzarin A**, Bonfanti M, Nappi C, Croce D. *Eur J Health Econ.* 2018 Jan;19(1):37-44. doi: 10.1007/s10198-016-0865-3. Epub 2016 Dec 22. PMID: 28008546

144

Cite

[Efficacy and safety of emtricitabine/tenofovir alafenamide \(FTC/TAF\) vs. emtricitabine/tenofovir disoproxil fumarate \(FTC/TDF\) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>](#)

Post FA, Yazdanpanah Y, Schembri G, **Lazzarin A**, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS. HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17. PMID: 28303753 Clinical Trial.

145

Cite

[Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.](#)

Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, **Lazzarin A**, Nelson M, McColl D, Andreatta K, Swamy R, Szwarcberg J, Nguyen T. HIV Clin Trials. 2017 May;18(3):118-125. doi: 10.1080/15284336.2017.1330440. Epub 2017 May 30. PMID: 28555519 Clinical Trial.

146

Cite

[Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.](#)

Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti-Foppa C, Castagna A, D'Avolio A, **Lazzarin A**, Bonora S, Hasson H. J Antimicrob Chemother. 2017 Mar 1;72(3):812-815. doi: 10.1093/jac/dkw492. PMID: 27999010

147

Cite

[Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.](#)

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, **Lazzarin A**, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM,



Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. PMID: 20085491 **Free PMC article.** Clinical Trial.

148

Cite

[Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy.](#)

Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, **Lazzarin A**, Castagna A. AIDS. 2014 Oct 23;28(16):2407-15. doi: 10.1097/QAD.0000000000000443. PMID: 25160933

149

Cite

[Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.](#)

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group. HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26. PMID: 26611175 **Free article.**

150

Cite

[NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.](#)

Morsica G, Andolina A, Merli M, Messina E, Hasson H, **Lazzarin A**, Uberti-Foppa C, Bagaglio S. Arch Virol. 2017 Aug;162(8):2271-2277. doi: 10.1007/s00705-017-3341-1. Epub 2017 Apr 18. PMID: 28421367

151

Cite

[Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection.](#)

Scarpellini P, Tasca S, Galli L, Beretta A, **Lazzarin A**, Fortis C. *J Clin Microbiol.* 2004 Aug;42(8):3469-74. doi: 10.1128/JCM.42.8.3469-3474.2004.PMID: 15297485 **Free PMC article.**

152

Cite

Share

[Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.](#)

Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, **Lazzarin A**. *J Acquir Immune Defic Syndr.* 2009 May 1;51(1):106-8. doi: 10.1097/QAI.0b013e3181a02fda.PMID: 19390331 No abstract available.

153

Cite

Share

[Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.](#)

Gjærde LI, Shepherd L, Jablonowska E, **Lazzarin A**, Rougemont M, Darling K, Battegay M, Braun D, Martel-Lafferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. *Clin Infect Dis.* 2016 Sep 15;63(6):821-829. doi: 10.1093/cid/ciw380. Epub 2016 Jun 15.PMID: 27307505 **Free PMC article.**

154

Cite

Share

[Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy.](#)

Camoni L, Raimondo M, Dorrucchi M, Regine V, Salfa MC, Suligo B; CARPHA Study Group. *AIDS Res Hum Retroviruses.* 2015 Mar;31(3):282-7. doi: 10.1089/AID.2014.0154. Epub 2015 Jan 6.PMID: 25432098 **Free PMC article.**

155

Cite

Share

[48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.](#)

Nozza S, Pignataro AR, Galli L, Svicher V, Alteri C, Boeri E, Ripa M, Castagna A, Sampaolo M, Clementi M, Perno CF, **Lazzarin A**. *New Microbiol.* 2016 Jul;39(3):192-196. PMID: 27704143 **Free article.** Clinical Trial.

156

Cite

Share

[The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.](#)

Cinque P, Nebuloni M, Santovito ML, Price RW, Gisslen M, Hagberg L, Bestetti A, Vago G, **Lazzarin A**, Blasi F, Sidenius N. *Ann Neurol.* 2004 May;55(5):687-94. doi: 10.1002/ana.20076. PMID: 15122709

157

Cite

Share

[Oral CCR5 inhibitors: will they make it through?](#)

Biswas P, Nozza S, Scarlatti G, **Lazzarin A**, Tambussi G. *Expert Opin Investig Drugs.* 2006 May;15(5):451-64. doi: 10.1517/13543784.15.5.451. PMID: 16634684 Review.

158

Cite

Share

[Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.](#)

Harari A, Rizzardi GP, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Kaufmann D, Telenti A, Sahli R, Tambussi G, Kaiser L, **Lazzarin A**, Perrin L, Pantaleo G. *Blood.* 2002 Aug 15;100(4):1381-7. doi: 10.1182/blood-2001-11-0080. PMID: 12149221 **Free article.**

159

Cite

Share

[Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.](#)

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. *J Antimicrob Chemother.* 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PMID: 26702926 **Free article.** Clinical Trial.

160

Cite

Share

[A pilot study of brisk walking in sedentary combination antiretroviral treatment \(cART\)- treated patients: benefit on soluble and cell inflammatory markers.](#)

Bonato M, Galli L, Passeri L, Longo V, Pavei G, Bossolasco S, Bertocchi C, Cernuschi M, Balconi G, Merati G, **Lazzarin A**, La Torre A, Cinque P. *BMC Infect Dis.* 2017 Jan 11;17(1):61. doi: 10.1186/s12879-016-2095-9. PMID: 28077069 **Free PMC article.**

161

Cite

Share

[Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males.](#)

Rovelli C, Poli A, Galli L, Cernuschi M, Tamburini AM, Racca S, Tambussi G, Rolla S, Albarello L, Rosati R, **Lazzarin A**, Castagna A, Nozza S. *PLoS One.* 2017 Oct 31;12(10):e0186367. doi: 10.1371/journal.pone.0186367. eCollection 2017. PMID: 29088236 **Free PMC article.**

162

Cite

Share

[Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.](#)

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, **Lazzarin A**, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. *Open Forum Infect Dis.* 2017 Jul 22;4(3):ofx154. doi: 10.1093/ofid/ofx154. eCollection 2017 Summer. PMID: 28948180 **Free PMC article.**

163

Cite

Share

[Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.](#)

Restelli U, Rizzardini G, Antinori A, **Lazzarin A**, Bonfanti M, Bonfanti P, Croce D. *Ther Clin Risk Manag.* 2017 Jun 29;13:787-797. doi: 10.2147/TCRM.S135972. eCollection 2017. PMID: 28721059 **Free PMC article.**

164

Cite

Share

[Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service.](#)

Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, **Lazzarin A**, Rizzardini G, Croce D. *Clinicoecon Outcomes Res.* 2014 Sep 23;6:409-14. doi: 10.2147/CEOR.S68101. eCollection 2014. PMID: 25285019 **Free PMC article.**

165

Cite

Share

[Progressive multifocal leukoencephalopathy \(PML\) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity.](#)

Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, **Lazzarin A**, Sunyaev S, Simon K, Cinque P. *J Infect Dis.* 2011 Jul 1;204(1):103-14. doi: 10.1093/infdis/jir198.PMID: 21628664 **Free PMC article.**

166

Cite

Share

[Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.](#)

Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, **Lazzarin A**, Miró JM, Sabin C; Late Presenter Investigators. *AIDS.* 2008 Nov 30;22(18):2461-9. doi: 10.1097/QAD.0b013e328314b5f1.PMID: 19005269

167

Cite

Share

[Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption.](#)

Mussini C, Touloumi G, Bakoyannis G, Sabin C, Castagna A, Sighinolfi L, Erikson LE, Bratt G, Borghi V, **Lazzarin A**, Cossarizza A, Esposito R. *J Acquir Immune Defic Syndr.* 2009 Dec;52(5):588-94. doi: 10.1097/qai.0b013e3181b9e94d.PMID: 19950432

168

Cite

Share

[Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study.](#)

Sulkowski MS, Fessel WJ, **Lazzarin A**, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P. *Hepatol Int.* 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16.PMID: 28210927 *Clinical Trial.*

169

Cite

Share

[Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study.](#)

Spagnuolo V, Travi G, Galli L, Cossarini F, Guffanti M, Gianotti N, Salpietro S, **Lazzarin A**, Castagna A. *Cancer*. 2013 Aug 1;119(15):2710-9. doi: 10.1002/cncr.28119. Epub 2013 Apr 26. PMID: 23625649 **Free article.**

170

Cite

Share

[Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.](#)

Ferretti F, Bigoloni A, Passeri L, Galli L, Longo V, Gerevini S, Spagnuolo V, Gisslen M, Zetterberg H, Fuchs D, Cattaneo D, Caramatti G, **Lazzarin A**, Cinque P, Castagna A. *Medicine (Baltimore)*. 2016 Jul;95(28):e4144. doi: 10.1097/MD.0000000000004144. PMID: 27428202 **Free PMC article.** *Clinical Trial.*

171

Cite

Share

[Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.](#)

Guffanti M, Caumo A, Galli L, Bigoloni A, Galli A, Dagba G, Danise A, Luzi L, **Lazzarin A**, Castagna A. *Eur J Endocrinol*. 2007 Apr;156(4):503-9. doi: 10.1530/EJE-06-0648. PMID: 17389467

172

Cite

Share

[Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.](#)

Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, Galli A, Castagna A, **Lazzarin A**. *AIDS*. 2003 Dec 5;17(18):2669-71. doi: 10.1097/00002030-200312050-00017. PMID: 14685066

173

Cite

Share

[Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis \(ABACUS\): a prospective observational study.](#)

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. *Lancet Gastroenterol Hepatol.* 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. PMID: 28497758

174

Cite

Share

[Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.](#)

Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Alice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. *New Microbiol.* 2012 Jan;35(1):17-25. Epub 2012 Jan 10. PMID: 22378549 **Free article.**

175

Cite

Share

[Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.](#)



Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, **Lazzarin A**, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups. *AIDS*. 2013 Mar 27;27(6):939-950. doi: 10.1097/QAD.0b013e32835cee6e.PMID: 23211772 Clinical Trial.

176

Cite

Share

[Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?](#)

Biswas P, Galli A, Galli L, Tassan Din C, Vecchi A, Malnati M, **Lazzarin A**, Tambussi G. *Cytometry B Clin Cytom*. 2007 Nov;72(6):433-41. doi: 10.1002/cyto.b.20352.PMID: 17474134 **Free article**. Clinical Trial.

177

Cite

Share

[Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.](#)

Armignacco O, Andreoni M, Sagnelli E, Puoti M, Bruno R, Gaeta GB, Perno CF, Santantonio TA, Bonfanti P, Bonora S, Borderi M, Castagna A, d'Arminio Monforte A, De Luca A, Grossi P, Guaraldi G, Maggiolo F, Mussini C, Sagnelli C, Tavio M, Torti C, Uberti-Foppa C, Andreoni M, Angarano G, Antinori A, Armignacco O, Carosi G, Chirianni A, Di Perri G, Galli M, **Lazzarin A**, Rizzardini G, Sagnelli E, Taliani G. *New Microbiol*. 2014 Oct;37(4):423-38. Epub 2014 Oct 1.PMID: 25387281 **Free article**.

178

Cite

Share

[Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection \(FLAMINGO\): 96 week results from a randomised, open-label, phase 3b study.](#)

Molina JM, Clotet B, van Lunzen J, **Lazzarin A**, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. *Lancet HIV*. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10.PMID: 26424673 Clinical Trial.

179

Cite

Share

[Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.](#)

de Requena DG, Bonora S, Castagna A, Hasson H, Marucco DA, D'Avolio A, Sciandra M, Trentini L, Calcagno A, **Lazzarin A**, Di Perri G. *J Antimicrob Chemother.* 2008 Aug;62(2):384-7. doi: 10.1093/jac/dkn192. Epub 2008 May 16. PMID: 18487231

180

Cite

Share

[TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.](#)

Sagnelli C, Merli M, Uberti-Foppa C, Hasson H, Grandone A, Cirillo G, Salpietro S, Minichini C, Starace M, Messina E, Morelli P, Miraglia Del Giudice E, **Lazzarin A**, Coppola N, Sagnelli E. *World J Gastroenterol.* 2016 Oct 14;22(38):8509-8518. doi: 10.3748/wjg.v22.i38.8509. PMID: 27784963 **Free PMC article.**

181

Cite

Share

[Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.](#)

Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, **Lazzarin A**, Ballesteros J, Sosa N, Van De Casteele T, DeMasi R, Spinosa-Guzman S, Lavreys L. *HIV Clin Trials.* 2011 Nov-Dec;12(6):313-22. doi: 10.1310/hct1206-313. PMID: 22189150 Clinical Trial.

182

Cite

Share

[HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.](#)

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, **Lazzarin A**, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. *Retrovirology*. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y. PMID: 25924841 **Free PMC article**. Clinical Trial.

183

Cite

Share

[Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.](#)

Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, **Lazzarin A**, Machala L, Phillips AN, Lundgren JD; EuroSIDA study group and the Swiss HIV Cohort Study. *AIDS*. 2007 Sep 12;21(14):1867-75. doi: 10.1097/QAD.0b013e328270b877. PMID: 17721094

184

Cite

Share

[Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings.](#)

Parisi MR, Soldini L, Vidoni G, Clemente F, Mabellini C, Belloni T, Nozza S, Brignolo L, Negri S, Rusconi S, Schlusnus K, Dorigatti F, **Lazzarin A**. *New Microbiol*. 2013 Apr;36(2):121-32. Epub 2013 Mar 31. PMID: 23686118 **Free article**.

185

Cite

Share

[Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.](#)

Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A; VEMAN Study Group. *Clin Microbiol Infect*. 2015

May;21(5):510.e1-9. doi: 10.1016/j.cmi.2014.12.006. Epub 2014 Dec 11.PMID: 25656621 **Free article.** Clinical Trial.

186

Cite

Share

[Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.](#)

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, **Lazzarin A**, Rijnders B, Podzamczar D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H.Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.PMID: 28259777 Clinical Trial.

187

Cite

Share

[Offer of rapid testing and alternative biological samples as practical tools to implement HIV screening programs.](#)

Parisi MR, Soldini L, Di Perri G, Tiberi S, **Lazzarin A**, Lillo FB.New Microbiol. 2009 Oct;32(4):391-6.PMID: 20128446 **Free article.**

188

Cite

Share

[Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.](#)

Soria A, Danise A, Galli L, Tiberi S, Seminari E, Cossarini F, Bigoloni A, Marcotullio S, **Lazzarin A**, Castagna A.J Clin Virol. 2010 Mar;47(3):253-7. doi: 10.1016/j.jcv.2009.12.007. Epub 2010 Jan 6.PMID: 20056480 Clinical Trial.

189

Cite

Share

[Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.](#)

Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. *Lancet HIV*. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30. PMID: 26520926 Clinical Trial.

190

Cite

Share

[Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.](#)

Gianotti N, Poli A, Nozza S, Spagnuolo V, Tambussi G, Bossolasco S, Cinque P, Maillard M, Cernuschi M, Galli L, **Lazzarin A**, Castagna A. *J Int AIDS Soc*. 2015 Jul 30;18(1):20037. doi: 10.7448/IAS.18.1.20037. eCollection 2015. PMID: 26232000 **Free PMC article.**

191

Cite

Share

[In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.](#)

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, **Lazzarin A**, Clementi M. *J Antimicrob Chemother*. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24. PMID: 23798668

192

Cite

Share

[Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.](#)

Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, **Lazzarin A**, Castagna A. *Medicine (Baltimore)*. 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.PMID: 27258510 **Free PMC article.**

193

Cite

Share

[Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.](#)

**Lazzarin A**, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnies C, Salgo M; TORO 2 Study Group. *N Engl J Med*. 2003 May 29;348(22):2186-95. doi: 10.1056/NEJMoa035211.PMID: 12773645 **Free article.** Clinical Trial.

194

Cite

Share

[The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.](#)

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, **Lazzarin A**, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. *Retrovirology*. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.PMID: 24961156 **Free PMC article.**

195

Cite

Share

[Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection \(ARIA\): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.](#)

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. *Lancet HIV*. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17.PMID: 28729158 Clinical Trial.

196

Cite

Share

[Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.](#)

Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, **Lazzarin A**, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. *J Infect Dis.* 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7. PMID: 23225901 **Free PMC article.** Clinical Trial.

197

Cite

Share

[Once-a-day \(QD\) vs. twice-daily \(BID\) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction.](#)

Maserati R, Brandolini M, Cattelan A, Orani A, Sighinolfi L, Andreoni M, Uglietti A, Guaraldi G, Sotgiu G; SNODO Study Group. *Curr HIV Res.* 2011 Apr;9(3):166-73. doi: 10.2174/157016211795945232. PMID: 21443516 Clinical Trial.

198

Cite

Share

[Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.](#)

Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G, **Lazzarin A**. *Am J Physiol Endocrinol Metab.* 2003 Feb;284(2):E274-80. doi: 10.1152/ajpendo.00391.2001. Epub 2002 Oct 8. PMID: 12388139 **Free article.**

199

Cite

Share

[Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2.](#)

Bossolasco S, Nozza S, Gaiera G, Bestetti A, **Lazzarin A**, Cinque P. *AIDS*. 2007 May 31;21(9):1223-5. doi: 10.1097/QAD.0b013e32810c8d27. PMID: 17502740 No abstract available.

200

Cite

Share

[Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients.](#)

Turriziani O, Butera O, Gianotti N, Parisi SG, Mazzi R, Girardi E, Iaiani G, Antonelli L, **Lazzarin A**, Antonelli G. *AIDS*. 2005 Mar 25;19(5):473-9. doi: 10.1097/01.aids.0000162335.12815.12. PMID: 15764852

201

Cite

Share

[Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV \(PHOTON-2\): a multicentre, open-label, non-randomised, phase 3 study.](#)

Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team. *Lancet*. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4. PMID: 25659285 **Free article**. *Clinical Trial*.

202

Cite

Share

[Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.](#)

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J,



Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team. *Lancet*. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. PMID: 23830355 Clinical Trial.

203

Cite

Share

[Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.](#)

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, **Lazzarin A**, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. *AIDS*. 2005 Apr 29;19(7):685-94. doi: 10.1097/01.aids.0000166091.39317.99. PMID: 15821394 Clinical Trial.

204

Cite

Share

[Acute hepatitis C: a 24-week course of pegylated interferon  \$\alpha\$ -2b versus a 12-week course of pegylated interferon  \$\alpha\$ -2b alone or with ribavirin.](#)

Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. *Hepatology*. 2014 Jun;59(6):2101-9. doi: 10.1002/hep.26991. Epub 2014 Apr 29. PMID: 24442928 Clinical Trial.

205

Cite

Share

[Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals.](#)

Furci L, Lopalco L, Loverro P, Sinnone M, Tambussi G, **Lazzarin A**, Lusso P. *AIDS*. 2002 May 3;16(7):1003-8. doi: 10.1097/00002030-200205030-00006. PMID: 11953466

206

Cite

Share

[Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.](#)

Hasson H, Merli M, Galli L, Gallotta G, Carbone A, Messina E, Bagaglio S, Morsica G, Salpietro S, Castagna A, **Lazzarin A**, Uberti-Foppa C. *Liver Int.* 2013 Aug;33(7):1113-20. doi: 10.1111/liv.12159. Epub 2013 Mar 28. PMID: 23534616

207

Cite

Share

[Significant link between sCD30 changes and HIV viremia in patients treated with HAART.](#)

Biswas P, Cozzi-Lepri A, Delfanti F, Galli A, Colangeli V, Moioli MC, Scarchilli A, Abrescia N, Vigevani G, D'Arminio-Monforte A, Novati R, **Lazzarin A**. *J Med Virol.* 2006 Dec;78(12):1513-9. doi: 10.1002/jmv.20733. PMID: 17063513 Clinical Trial.

208

Cite

Share

[The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.](#)

Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, **Lazzarin A**, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF. *AIDS.* 2007 Jun 19;21(10):1273-81. doi: 10.1097/QAD.0b013e3280b07b33. PMID: 17545703

209

Cite

Share

[Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.](#)

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A;

NEAT001/ANRS143 Study Group. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. PMID: 25103176 Clinical Trial.

210

Cite

Share

[Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.](#)

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12. PMID: 23768747 Clinical Trial.

211

Cite

Share

[Efficacy and safety of lersivirine \(UK-453,061\) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.](#)

Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, **Lazzarin A**, Valdez H, Goodrich J, Mori J, Craig C, Tawadrous M. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):171-9. doi: 10.1097/QAI.0b013e31827a2ba2.. PMID: 23328090 Clinical Trial.

212

Cite

Share

[Safety profile of maraviroc in patients coinfecting with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.](#)

**Lazzarin A**, Than S, Valluri SR, Heera J, Mukwaya G. HIV Clin Trials. 2012 Mar-Apr;13(2):83-9. doi: 10.1310/hct1302-83. PMID: 22510355 Clinical Trial.

213

Cite

Share

[Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.](#)

Gianotti N, Poli A, Galli M, Pan A, Rizzardini G, Soria A, Viale P, Di Biagio A, Quirino T, Viganò P, Bonfanti P, d'Arminio Monforte A, Fortino I, **Lazzarin A**. *New Microbiol.* 2014 Oct;37(4):439-48. Epub 2014 Oct 1. PMID: 25387282 **Free article.** Clinical Trial.

214

Cite

Share

[Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.](#)

Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, **Lazzarin A**. *Antivir Ther.* 2010;15(2):165-75. doi: 10.3851/IMP1513. PMID: 20386071 Clinical Trial.

215

Cite

Share

[Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis.](#)

Tasca S, Tambussi G, Nozza S, Capiluppi B, Zocchi MR, Soldini L, Veglia F, Poli G, **Lazzarin A**, Fortis C. *AIDS.* 2003 Nov 7;17(16):2291-8. doi: 10.1097/00002030-200311070-00003. PMID: 14571180

216

Cite

Share

[Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.](#)

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, **Lazzarin A**, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. *N Engl J Med*. 2004 Jul 29;351(5):438-50. doi: 10.1056/NEJMoa040842.PMID: 15282351 **Free article**. Clinical Trial.

217

Cite

Share

[TMC114/ritonavir substitution for protease inhibitor\(s\) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.](#)

Arastéh K, Clumeck N, Pozniak A, **Lazzarin A**, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E; TMC114-C207 Study Team. *AIDS*. 2005 Jun 10;19(9):943-7. doi: 10.1097/01.aids.0000171408.38490.01.PMID: 15905675 Clinical Trial.

218

Cite

Share

[96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.](#)

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, **Lazzarin A**, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C. *AIDS*. 2006 Mar 21;20(5):711-8. doi: 10.1097/01.aids.0000216371.76689.63.PMID: 16514301 Clinical Trial.

219

Cite

Share

[Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.](#)

Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, Gisslen M, Hagberg L, Vago L, **Lazzarin A**, Blasi F, Cinque P. *J Neuroimmunol*. 2004 Dec;157(1-2):133-9. doi: 10.1016/j.jneuroim.2004.08.038.PMID: 15579290

220

Cite

Share

[Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.](#)

Katlama C, Haubrich R, Lalezari J, **Lazzarin A**, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. *AIDS*. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.PMID: 19710593 Clinical Trial.

221

Cite

Share

[Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.](#)

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, **Lazzarin A**, Wan H, Walker ML, Xu X, Zhao J, Tepler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. *Clin Infect Dis*. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.PMID: 21921224 Clinical Trial.

222

Cite

Share

[Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.](#)

Rizzardì GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, **Lazzarin A**, Pantaleo G. *J Clin Invest*. 2002 Mar;109(5):681-8. doi: 10.1172/JCI14522.PMID: 11877476 **Free PMC article**. Clinical Trial.

223

Cite

Share

[The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.](#)

Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arastéh K, Chung J, Rowell L, Guimaraes D, Bertasso A; TORO 1 and TORO 2 Study Groups. *HIV Med.* 2011 Jan;12(1):31-9. doi: 10.1111/j.1468-1293.2010.00845.x.PMID: 20497250 **Free article.** Clinical Trial.

224

Cite

Share

[A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.](#)

Opravil M, Hirschel B, **Lazzarin A**, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L; Swiss HIV Cohort Study. *J Infect Dis.* 2002 May 1;185(9):1251-60. doi: 10.1086/340312. Epub 2002 Apr 1.PMID: 12001042 **Free article.** Clinical Trial.

225

Cite

Share

[Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.](#)

Gatell JM, Katlama C, Grinsztejn B, Eron JJ, **Lazzarin A**, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY; Protocol 005 Team. *J Acquir Immune Defic Syndr.* 2010 Apr 1;53(4):456-63. doi: 10.1097/qai.0b013e3181c9c967.PMID: 20306554 **Free PMC article.** Clinical Trial.

226

Cite

Share

[Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.](#)

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, **Lazzarin A**. *Ther Clin Risk Manag.* 2014;10:9-15. doi: 10.2147/TCRM.S49428. Epub 2013 Dec 18.PMID: 24379676 **Free PMC article.**

227

Cite

Share

[The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.](#)

Castagna A, Biswas P, Beretta A, **Lazzarin A**. *Drugs*. 2005;65(7):879-904. doi: 10.2165/00003495-200565070-00001.PMID: 15892586

228

Cite

Share

[Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.](#)

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, **Lazzarin A**, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams. *Lancet Infect Dis*. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.PMID: 23664333 **Free PMC article**. Clinical Trial.

229

Cite

Share

[Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection.](#)

Mantegani P, Piana F, Codecasa L, Galli L, Scarpellini P, **Lazzarin A**, Cirillo D, Fortis C. *Clin Med Res*. 2006 Dec;4(4):266-72. doi: 10.3121/cmr.4.4.266.PMID: 17210976 **Free PMC article**. Clinical Trial.

230

Cite

Share



[Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.](#)

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, **Lazzarin A**, Clementi M, Gianotti N. *AIDS*. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60. PMID: 19165083

231

Cite

Share

[Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study \(E-184V study\).](#)

Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, **Lazzarin A**. *AIDS*. 2006 Apr 4;20(6):795-803. doi: 10.1097/01.aids.0000218542.08845.b2. PMID: 16549962 Clinical Trial.

232

Cite

Share

[Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.](#)

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, **Lazzarin A**, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group. *AIDS*. 2008 Oct 18;22(16):2187-98. doi: 10.1097/QAD.0b013e328310e04f. PMID: 18832882

233

Cite

Share

[Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.](#)

Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, **Lazzarin A**, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. *Pharmacogenet Genomics*. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. PMID: 21217360 Clinical Trial.

234

Cite

Share

[Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.](#)

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, **Lazzarin A**, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H; ASSERT Study Group. *Clin Infect Dis.* 2010 Oct 15;51(8):963-72. doi: 10.1086/656417.PMID: 20828304 Clinical Trial.

235

Cite

Share

[Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy.](#)

Buonaguro L, Tagliamonte M, Tornesello ML, Pilotti E, Casoli C, **Lazzarin A**, Tambussi G, Ciccozzi M, Rezza G, Buonaguro FM; Italian Concerted Action on PHI Treatment. *J Acquir Immune Defic Syndr.* 2004 Oct 1;37(2):1295-306. doi: 10.1097/01.qai.0000123273.76723.04.PMID: 15385738

236

Cite

Share

[Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma.](#)

Bossolasco S, Cinque P, Ponzoni M, Viganò MG, **Lazzarin A**, Linde A, Falk KI. *J Neurovirol.* 2002 Oct;8(5):432-8. doi: 10.1080/13550280260422730.PMID: 12402169

237

Cite

Share

[Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.](#)

Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, **Lazzarin A**, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. *PLoS One*. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.PMID: 21085635 **Free PMC article**. Clinical Trial.

238

Cite

Share

[Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 \(ECHO\): a phase 3 randomised double-blind active-controlled trial.](#)

Molina JM, Cahn P, Grinsztejn B, **Lazzarin A**, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group. *Lancet*. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.PMID: 21763936 Clinical Trial.

239

Cite

Share

[Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.](#)

Mantegani P, Tambussi G, Galli L, Din CT, **Lazzarin A**, Fortis C. *Immunology*. 2010 Feb;129(2):220-33. doi: 10.1111/j.1365-2567.2009.03171.x. Epub 2009 Aug 4.PMID: 19824914 **Free PMC article**.

240

Cite

Share

[Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.](#)

Bonsel M, Pastori C, Tudor D, Alberti C, Garcia S, Ferrari D, **Lazzarin A**, Lopalco L. *AIDS*. 2007 Jan 2;21(1):13-22. doi: 10.1097/QAD.0b013e328011049b.PMID: 17148963

241

Cite

Share

[Neurobrucellosis with spinal cord abscess of the dorsal tract: a case report.](#)

Novati R, Viganò MG, de Bona A, Nocita B, Finazzi R, **Lazzarin A**. *Int J Infect Dis.* 2002 Jun;6(2):149-50. doi: 10.1016/s1201-9712(02)90079-2. PMID: 12146501 **Free article.** No abstract available.

242

Cite

Share

[Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study.](#)

Santoro MM, Bertoli A, Lorenzini P, **Lazzarin A**, Esposito R, Carosi G, Di Perri G, Filice G, Moroni M, Rizzardini G, Caramello P, Maserati R, Narciso P, Cargnel A, Antinori A, Perno CF; CARE Study Group. *AIDS Patient Care STDS.* 2008 Jan;22(1):7-16. doi: 10.1089/apc.2007.0013. PMID: 18095835 **Clinical Trial.**

243

Cite

Share

[Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects.](#)

Scarpellini P, Carrera P, Cavallero A, Cernuschi M, Mezzi G, Testoni PA, Zingale A, **Lazzarin A**. *J Clin Microbiol.* 2002 Jun;40(6):2234-7. doi: 10.1128/JCM.40.6.2234-2237.2002. PMID: 12037095 **Free PMC article.**

244

Cite

Share

[Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy.](#)

Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, **Lazzarin A.** *J Antimicrob Chemother.* 2006 Apr;57(4):796-8. doi: 10.1093/jac/dkl016. Epub 2006 Feb 9. PMID: 16469850 No abstract available.

245

Cite

Share

[Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels.](#)

Uberti-Foppa C, De Bona A, Galli L, Sitia G, Gallotta G, Sagnelli C, Paties C, **Lazzarin A.** *J Acquir Immune Defic Syndr.* 2006 Jan 1;41(1):63-7. doi: 10.1097/01.qai.0000192001.15777.15. PMID: 16340475

246

Cite

Share

[Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply.](#)

Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, **Lazzarin A,** Castagna A. *AIDS.* 2015 Apr 24;29(7):857-9. doi: 10.1097/QAD.0000000000000585. PMID: 25985407 No abstract available.

247

Cite

Share

[Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.](#)

Morsica G, Bruno R, Bagaglio S, De Mitri MS, Andreone P, **Lazzarin A.** *AIDS.* 2004 Apr 30;18(7):1080-2. doi: 10.1097/00002030-200404300-00022. PMID: 15096817 Clinical Trial. No abstract available.

248

Cite

Share

[Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.](#)

Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, **Lazzarin A**, Castagna A. *J Antimicrob Chemother.* 2007 Oct;60(4):831-6. doi: 10.1093/jac/dkm282. Epub 2007 Aug 7. PMID: 17684056

249

Cite

Share

[Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.](#)

Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, **Lazzarin A**, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelov T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. *J Acquir Immune Defic Syndr.* 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c. PMID: 16280695 Clinical Trial.

250

Cite

Share

[TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.](#)

Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, **Lazzarin A**, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatucci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP. *AIDS Patient Care STDS.* 2007 Aug;21(8):533-43. doi: 10.1089/apc.2006.0174. PMID: 17711378 Clinical Trial.

251

Cite

Share

[Immortal time bias: authors' reply.](#)

Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, **Lazzarin A**, Castagna A. *AIDS*. 2015 Apr 24;29(7):860-1. doi: 10.1097/QAD.0000000000000583. PMID: 25985409 No abstract available.

252

Cite

Share

[Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.](#)

Lennox JL, DeJesus E, **Lazzarin A**, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators. *Lancet*. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. PMID: 19647866 *Clinical Trial*.

253

Cite

Share

[Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.](#)

Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, **Lazzarin A**, Antonelli G. *J Med Virol*. 2008 May;80(5):766-71. doi: 10.1002/jmv.21152. PMID: 18360888

254

Cite

Share

[CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in gamma delta T lymphocytes.](#)

Biswas P, Mantelli B, Delfanti F, Ferrarini M, Poli G, **Lazzarin A**. *Eur J Immunol*. 2003 Nov;33(11):3136-45. doi: 10.1002/eji.200324344. PMID: 14579282 **Free article**.

255

Cite

Share

[Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.](#)

Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, Sala S, **Lazzarin A**, Cinque P. *Clin Infect Dis*. 2005 Mar 1;40(5):738-44. doi: 10.1086/427698. Epub 2005 Feb 1. PMID: 15714422

256

Cite

Share

[Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters.](#)

Beretta A, Hasson H, Samiabadi A, Alfano M, Trabattoni D, Lillo F, Ferrante P, Clerici M, **Lazzarin A**. *Perfusion*. 2002 May;17 Suppl:47-51. doi: 10.1191/0267659102pf559oa. PMID: 12009086

257

Cite

Share

[Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.](#)

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, **Lazzarin A**, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. *Clin Infect Dis*. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. PMID: 17599319 **Free article.**

258

Cite

Share



[Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.](#)

Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Kenna PM, **Lazzarin A**; Mutations and Salvage (MuSa) Study Group. *Clin Infect Dis*. 2006 May 15;42(10):1470-80. doi: 10.1086/503568. Epub 2006 Apr 13. PMID: 16619162 Clinical Trial.

259

Cite

Share

[Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.](#)

Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, Longhi R, Calori G, Burger H, Kemal K, Poli G, **Lazzarin A**, Lopalco L. *Blood*. 2006 Jun 15;107(12):4825-33. doi: 10.1182/blood-2005-06-2463. Epub 2006 Mar 7. PMID: 16522810 **Free PMC article.**

260

Cite

Share

[Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance.](#)

Broccolo F, Bossolasco S, Careddu AM, Tambussi G, **Lazzarin A**, Cinque P. *Clin Diagn Lab Immunol*. 2002 Nov;9(6):1222-8. doi: 10.1128/cdli.9.6.1222-1228.2002. PMID: 12414753 **Free PMC article.**

261

Cite

Share

[Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.](#)

Mussini C, Pezzotti P, Miró JM, Martinez E, de Quiros JC, Cinque P, Borghi V, Bedini A, Domingo P, Cahn P, Bossi P, de Luca A, d'Arminio Monforte A, Nelson M, Nwokolo N, Helou S, Negroni R, Jacchetti G, Antinori S, **Lazzarin A**, Cossarizza A, Esposito R, Antinori A, Aberg JA; International Working Group on

Cryptococcosis. Clin Infect Dis. 2004 Feb 15;38(4):565-71. doi: 10.1086/381261. Epub 2004 Jan 29. PMID: 14765351 **Free article.**

262

Cite

Share

[Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.](#)

Bagaglio S, Cinque P, Racca S, Pedale R, Grasso MA, **Lazzarin A**, Morsica G. AIDS. 2005 Oct;19 Suppl 3:S151-65. doi: 10.1097/01.aids.0000192085.87302.39. PMID: 16251813

263

Cite

Share

[Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.](#)

Squires K, **Lazzarin A**, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003. PMID: 15247553 Clinical Trial.

264

Cite

Share

[NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short- versus long-term cultured human gamma delta lymphocytes.](#)

Ferrarini M, Delfanti F, Gianolini M, Rizzi C, Alfano M, **Lazzarin A**, Biswas P. J Immunol. 2008 Nov 1;181(9):5857-64. doi: 10.4049/jimmunol.181.9.5857. PMID: 18941174

265

Cite

Share

[Immune recovery and T cell subset analysis during effective treatment with maraviroc.](#)

Cossarini F, Galli A, Galli L, Bigoloni A, Salpietro S, Vinci C, Della Torre L, Gianotti N, Spagnuolo V, **Lazzarin A**, Castagna A, Nozza S. *J Antimicrob Chemother.* 2012 Oct;67(10):2474-8. doi: 10.1093/jac/dks216. Epub 2012 Jun 7. PMID: 22678730

266

Cite

Share

[Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.](#)

Hasson H, Mantelli B, Biswas P, Malnati M, Gianotti N, Vecchi A, Nozza S, Cernuschi M, Boeri E, Clerici M, **Lazzarin A**, Beretta A. *J Med Virol.* 2007 Nov;79(11):1640-9. doi: 10.1002/jmv.20977. PMID: 17854028 Clinical Trial.

267

Cite

Share

[Efficacy and safety of TMC125 \(etravirine\) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.](#)

**Lazzarin A**, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group. *Lancet.* 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4. PMID: 17617271 Clinical Trial.

268

Cite

Share

[Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.](#)

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. *Antimicrob Agents*

Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. PMID: 19451297 **Free PMC article.** Clinical Trial.

269

Cite

Share

[Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays.](#)

Broccolo F, Scarpellini P, Locatelli G, Zingale A, Brambilla AM, Cichero P, Sechi LA, **Lazzarin A**, Lusso P, Malnati MS. J Clin Microbiol. 2003 Oct;41(10):4565-72. doi: 10.1128/JCM.41.10.4565-4572.2003. PMID: 14532183 **Free PMC article.**

270

Cite

Share

[Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients \(BI Study 1182.51\).](#)

Walmsley SL, Katlama C, **Lazzarin A**, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG. J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. doi: 10.1097/QAI.0b013e318160a529. PMID: 18176328 Clinical Trial.

271

Cite

Share

[Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.](#)

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, **Lazzarin A**, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups. Lancet. 2007 Apr 7;369(9568):1169-78. doi: 10.1016/S0140-6736(07)60497-8. PMID: 17416261 Clinical Trial.

272

Cite

Share

[Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study \(AI424-097\) 48-week results.](#)

Gatell J, Salmon-Ceron D, **Lazzarin A**, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group. *Clin Infect Dis*. 2007 Jun 1;44(11):1484-92. doi: 10.1086/517497. Epub 2007 Apr 25. PMID: 17479947 Clinical Trial.

273

Cite

Share

[Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.](#)

Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, **Lazzarin A**, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. *J Acquir Immune Defic Syndr*. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0. PMID: 18545152 Clinical Trial.

274

Cite

Share

[Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.](#)

Cahn P, Villacian J, **Lazzarin A**, Katlama C, Grinsztejn B, Arasteh K, López P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. *Clin Infect Dis*. 2006 Nov 15;43(10):1347-56. doi: 10.1086/508352. Epub 2006 Oct 17. PMID: 17051504 Clinical Trial.

275

Cite

Share

[Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.](#)

Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, **Lazzarin A**, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD; EuroSIDA study group. *J Infect Dis.* 2006 Sep 1;194(5):633-41. doi: 10.1086/506366. Epub 2006 Jul 24. PMID: 16897662 **Free article.**

276

Cite

Share

[Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.](#)

Bagaglio S, Messina E, Uberti-Foppa C, Merli M, Torre LD, **Lazzarin A**, Hasson H, Morsica G. *J Antimicrob Chemother.* 2013 Jun;68(6):1448-50. doi: 10.1093/jac/dkt019. Epub 2013 Feb 6. PMID: 23390206 No abstract available.

277

Cite

Share

[Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection.](#)

Cossarini F, Boeri E, Canducci F, Salpietro S, Bigoloni A, Galli L, Spagnuolo V, Castagna A, Clementi M, **Lazzarin A**, Gianotti N. *J Acquir Immune Defic Syndr.* 2011 Feb 1;56(2):e51-4. doi: 10.1097/QAI.0b013e3181fcc0f1. PMID: 21233631 No abstract available.

278

Cite

Share

[Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.](#)

Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, **Lazzarin A**, Di Perri G. *J Antimicrob Chemother.* 2011 Aug;66(8):1932-4. doi: 10.1093/jac/dkr219. Epub 2011 Jun 4. PMID: 21642649 No abstract available.

279

Cite

Share

[Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.](#)

Soria A, Cavarelli M, Sala S, Alessandrini AI, Scarlatti G, **Lazzarin A**, Castagna A. *J Med Virol.* 2008 Jun;80(6):937-41. doi: 10.1002/jmv.21138.PMID: 18428138

280

Cite

Share

[Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir \(RESIST\) studies: an analysis of combined data from two randomised open-label trials.](#)

Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, **Lazzarin A**, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. *Lancet.* 2006 Aug 5;368(9534):466-75. doi: 10.1016/S0140-6736(06)69154-X.PMID: 16890833

281

Cite

Share

[Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.](#)

Bossolasco S, Falk KI, Ponzoni M, Ceserani N, Crippa F, **Lazzarin A**, Linde A, Cinque P. *Clin Infect Dis.* 2006 Feb 15;42(4):e21-5. doi: 10.1086/499956. Epub 2006 Jan 11.PMID: 16421782

282

Cite

Share

[Determination of human papillomavirus \(HPV\) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection.](#)

Lillo FB, Lodini S, Ferrari D, Stayton C, Taccagni G, Galli L, **Lazzarin A**, Uberti-Foppa C. Clin Infect Dis. 2005 Feb 1;40(3):451-7. doi: 10.1086/427032. Epub 2005 Jan 7. PMID: 15668870

283

Cite

Share

[The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS.](#)

Contini C, Cultrera R, Seraceni S, Segala D, Romani R, Fainardi E, Cinque P, **Lazzarin A**, Delia S. J Med Microbiol. 2002 Oct;51(10):879-890. doi: 10.1099/0022-1317-51-10-879. PMID: 12435069

284

Cite

Share

[An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection.](#)

Codecasa L, Mantegani P, Galli L, **Lazzarin A**, Scarpellini P, Fortis C. J Clin Microbiol. 2006 Jun;44(6):1944-50. doi: 10.1128/JCM.02265-05. PMID: 16757583 **Free PMC article.**

285

Cite

Share

[Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.](#)

Fortis C, Soldini L, Ghezzi S, Colombo S, Tambussi G, Vicenzi E, Gianotti N, Nozza S, Veglia F, Murone M, **Lazzarin A**, Poli G. AIDS Res Hum Retroviruses. 2002 May 1;18(7):491-9. doi: 10.1089/088922202317406637. PMID: 12015902 Clinical Trial.

286

Cite



Share

[Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.](#)

Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, **Lazzarin A**, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. *J Antimicrob Chemother.* 2011 Apr;66(4):901-11. doi: 10.1093/jac/dkr006. Epub 2011 Jan 31. PMID: 21393179

287

Cite

Share

[A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: implications for large scale monitoring of HIV-infected patients in resource-limited settings.](#)

Barbesti S, Soldini L, Carcelain G, Guignet A, Colizzi V, Mantelli B, Corvaglia A, Tran-Minh T, Dorigatti F, Autran B, **Lazzarin A**, Beretta A. *Cytometry B Clin Cytom.* 2005 Nov;68(1):43-51. doi: 10.1002/cyto.b.20068. PMID: 16184613 **Free article.**

288

Cite

Share

[Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.](#)

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, **Lazzarin A**, Montaner JS, O'Hearn M, Piliro PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatucci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. *J Acquir Immune Defic Syndr.* 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. PMID: 16280694 Clinical Trial.

289

Cite

Share

[Safety and efficacy of the HIV-1 integrase inhibitor raltegravir \(MK-0518\) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.](#)

Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, **Lazzarin A**, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team. *Lancet*. 2007 Apr 14;369(9569):1261-1269. doi: 10.1016/S0140-6736(07)60597-2. PMID: 17434401 Clinical Trial.

290

Cite

Share

[Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.](#)

Spagnuolo V, Gianotti N, Seminari E, Galli L, Fusetti G, Salpietro S, **Lazzarin A**, Castagna A. *J Acquir Immune Defic Syndr*. 2009 Feb 1;50(2):192-5. doi: 10.1097/QAI.0b013e31819367fc. PMID: 19131889

291

Cite

Share

[Cross-resistance profile of the novel integrase inhibitor Dolutegravir \(S/GSK1349572\) using clonal viral variants selected in patients failing raltegravir.](#)

Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, **Lazzarin A**, Clementi M. *J Infect Dis*. 2011 Dec 1;204(11):1811-5. doi: 10.1093/infdis/jir636. Epub 2011 Oct 7. PMID: 21984737

292

Cite

Share

[A case of HIV-associated fever of unknown origin: deficit of IL-1beta antagonistic activity and resolution with monocyte-granulocyte apheresis.](#)

Hasson H, Nozza S, Mantelli B, Biswas P, **Lazzarin A**, Beretta A. *AIDS*. 2006 Jan 9;20(2):312-3. doi: 10.1097/01.aids.0000196169.50303.78. PMID: 16511438 No abstract available.

293

Cite

Share

[Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.](#)

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, **Lazzarin A**, Garcia F, Ellefsen K, Podzamczar D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. *Lancet Infect Dis.* 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11. PMID: 24525316 Clinical Trial.

294

Cite

Share

[Comparison of a commercial and an in-house T cell-based assay for the diagnosis of Mycobacterium tuberculosis infection.](#)

Mantegani P, Piana F, Galli L, Scarpellini P, Codecasa L, **Lazzarin A**, Cirillo D, Fortis C. *New Microbiol.* 2007 Jul;30(3):291-4. PMID: 17802912 **Free article.**

295

Cite

Share

[Sustained virological response after ten days of triple anti-hepatitis C virus \(HCV\) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.](#)

Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, **Lazzarin A**, Uberti-Foppa C. *Int J Infect Dis.* 2014 Dec;29:100-2. doi: 10.1016/j.ijid.2014.08.011. Epub 2014 Oct 24. PMID: 25449243 **Free article.**

296

Cite

Share

[Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT \(CCR102881\) study.](#)

Currier J, **Lazzarin A**, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J; ASCENT study team. *Antivir Ther.* 2008;13(2):297-306.PMID: 18505181 Clinical Trial.

297

Cite

Share

[Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.](#)

Ghosh J, Carosi G, Moreno S, Pokrovsky V, **Lazzarin A**, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF. *Antivir Ther.* 2010;15(7):993-1002. doi: 10.3851/IMP1666.PMID: 21041914 Clinical Trial.

298

Cite

Share

[Highlights on HIV eradication in 2013.](#)

Monforte Ad, Svicher V, Nozza S, **Lazzarin A**, Marchetti G, Perno CF. *AIDS.* 2014 Jan 2;28(1):1-7. doi: 10.1097/01.aids.0000433241.78739.79.PMID: 23939240 **Free article.** No abstract available.

299

Cite

Share

[Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women.](#)

Uberti-Foppa C, Ferrari D, Lodini S, Reina S, Ameglio F, Grasso MA, Gallotta G, Ferrari A, Taccagni G, **Lazzarin A**, Lillo FB. *AIDS.* 2003 Sep 26;17(14):2136-8. doi: 10.1097/00002030-200309260-00021.PMID: 14502023 No abstract available.

300

Cite

Share

[CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects.](#)

Barassi C, **Lazzarin A**, Lopalco L. Blood. 2004 Oct 1;104(7):2205-6. doi: 10.1182/blood-2004-06-2134.PMID: 15377578 **Free article**. No abstract available.

301

Cite

Share

[Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.](#)

Ceresola ER, Nozza S, Sampaolo M, Pignataro AR, Saita D, Ferrarese R, Ripa M, Deng W, Mullins JI, Boeri E, Tambussi G, Toniolo A, **Lazzarin A**, Clementi M, Canducci F. J Antimicrob Chemother. 2015 May;70(5):1391-5. doi: 10.1093/jac/dku573. Epub 2015 Jan 20.PMID: 25608585 **Free PMC article**.

302

Cite

Share

[Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.](#)

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, **Lazzarin A**, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. AIDS. 2005 Jan 28;19(2):153-62. doi: 10.1097/00002030-200501280-00007.PMID: 15668540 **Corrected and republished**. No abstract available.

303

Cite

Share

[HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy.](#)

Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, Galli L, Clementi M, **Lazzarin A**, Castagna A. J Med Virol. 2008 Feb;80(2):201-8. doi: 10.1002/jmv.21085.PMID: 18098142

304

Cite

Share

[Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.](#)

Guffanti M, Gaiera G, Bossolasco S, Ceserani N, Ratti D, Cinque P, Salmaso F, Gianotti N, **Lazzarin A**. *Am J Trop Med Hyg.* 2008 Nov;79(5):715-8. PMID: 18981510

305

Cite

Share

[Virological rebound after suppression on highly active antiretroviral therapy.](#)

Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, **Lazzarin A**, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group. *AIDS.* 2003 Aug 15;17(12):1741-51. doi: 10.1097/00002030-200308150-00003. PMID: 12891060

306

Cite

Share

[Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfecting patients treated with antiretroviral therapy.](#)

Sitia G, De Bona A, Bagaglio S, Galli L, Paties CT, Uberti-Foppa C, Guidotti LG, **Lazzarin A**, Morsica G. *Antivir Ther.* 2006;11(3):385-9. PMID: 16759056

307

Cite

Share

[Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.](#)

Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, **Lazzarin A**, Marriott D, Muñoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. HIV Clin Trials. 2006 Mar-Apr;7(2):86-96. doi: 10.1310/2xvk-pbgl-735n-wh72.PMID: 16798623

308

Cite

Share

[Hepatitis C virus \(HCV\) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.](#)

Morsica G, Bagaglio S, Ghezzi S, Lodrini C, Vicenzi E, Santagostino E, Gringeri A, Cusini M, Carminati G, Bianchi G, Galli L, **Lazzarin A**, Poli G. J Clin Virol. 2007 Jun;39(2):82-6. doi: 10.1016/j.jcv.2007.03.007. Epub 2007 Apr 16. PMID: 17434339

309

Cite

Share

[Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals.](#)

Torre D, Speranza F, Ghezzi S, Nozza S, Tambussi G, Soldini L, Dorigatti F, **Lazzarin A**, Tambini R, Poli G. HIV Clin Trials. 2004 May-Jun;5(3):146-51. doi: 10.1310/MB7D-MKTM-QPG5-HHUD.PMID: 15248139

310

Cite

Share

[Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals.](#)

Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, Castagna A, **Lazzarin A**. AIDS. 2003 Sep 5;17(13):1993-5. doi: 10.1097/00002030-200309050-00022.PMID: 12960836

311

Cite

Share

[Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.](#)

Gianotti N, Galli L, Danise A, Hasson H, Boeri E, **Lazzarin A**, Castagna A. *J Med Virol.* 2006 Dec;78(12):1537-41. doi: 10.1002/jmv.20736.PMID: 17063520

312

Cite

Share

[Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection.](#)

Biswas P, Ferrarini M, Mantelli B, Fortis C, Poli G, **Lazzarin A**, Manfredi AA. *Eur J Immunol.* 2003 Jan;33(1):252-63. doi: 10.1002/immu.200390028.PMID: 12594854 **Free article.**

313

Cite

Share

[Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis.](#)

Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, **Lazzarin A**, Uberti-Foppa C, Cinque P. *J Clin Microbiol.* 2003 Nov;41(11):5080-4. doi: 10.1128/JCM.41.11.5080-5084.2003.PMID: 14605142 **Free PMC article.**

314

Cite

Share

[GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study.](#)

Luzi L, Meneghini E, Oggionni S, Tambussi G, Piceni-Sereni L, **Lazzarin A**. *Eur J Endocrinol.* 2005 Dec;153(6):781-9. doi: 10.1530/eje.1.02039.PMID: 16322383 *Clinical Trial.*



315

Cite

Share

[Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza \(GenPheRex\) trial.](#)

Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, **Lazzarin A**, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. *J Acquir Immune Defic Syndr.* 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005.PMID: 12626886 Clinical Trial.

316

Cite

Share

[Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.](#)

Hornberger J, Green J, Wintfeld N, Cavassini M, Rockstroh J, Giuliani G, De Carli C, **Lazzarin A**. *HIV Clin Trials.* 2005 Mar-Apr;6(2):92-102. doi: 10.1310/REJM-TAFW-0A7T-97UA.PMID: 15983893

317

Cite

Share

[Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients.](#)

Burastero SE, Paolucci C, Breda D, Soldarini A, Dorigatti F, Soprana E, Hasson H, Biswas P, **Lazzarin A**, Castagna A. *J Clin Immunol.* 2006 Mar;26(2):168-76. doi: 10.1007/s10875-006-9005-7. Epub 2006 Apr 7.PMID: 16602031

318

Cite

Share

[Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients.](#)

Sagnelli C, Uberti-Foppa C, Galli L, Pasquale G, Coppola N, Albarello L, Doglioni C, **Lazzarin A**, Sagnelli E. *Braz J Infect Dis*. 2014 Mar-Apr;18(2):164-9. doi: 10.1016/j.bjid.2013.06.005. Epub 2013 Oct 25. PMID: 24650995 **Free PMC article.**

319

Cite

Share

[The maraviroc expanded access program - safety and efficacy data from an open-label study.](#)

**Lazzarin A**, Reynes J, Molina JM, Valluri S, Mukwaya G, Heera J, Craig C, van der Ryst E, Sierra-Madero JG. *HIV Clin Trials*. 2015 Jan-Feb;16(1):10-21. doi: 10.1179/1528433614Z.0000000002. Epub 2015 Jan 23. PMID: 25777185

320

Cite

Share

[Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.](#)

Gianotti N, Seminari E, Fusetti G, Salpietro S, Boeri E, Galli A, **Lazzarin A**, Clementi M, Castagna A. *AIDS*. 2004 Nov 5;18(16):2205-8. doi: 10.1097/00002030-200411050-00016. PMID: 15577657

321

Cite

Share

[Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns.](#)

Galli M, Veglia F, Angarano G, Santambrogio S, Meneghini E, Gritti F, Cargnel A, Mazzotta F, **Lazzarin A**. *J Acquir Immune Defic Syndr*. 2003 Sep 1;34(1):58-61. doi: 10.1097/00126334-200309010-00008. PMID: 14501794

322

Cite

Share

[Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine.](#)

Carbone A, Bigoloni A, Galli L, Spagnuolo V, Gianotti N, **Lazzarin A**, Castagna A. *AIDS*. 2013 Oct 23;27(16):2661-3. doi: 10.1097/01.aids.0000432464.31132.86.PMID: 24096632 No abstract available.

323

Cite

Share

[Monotherapy with atazanavir as a simplification strategy: results from an observational study.](#)

Cossarini F, Salpietro S, Galli L, Gianotti N, Nozza S, Spagnuolo V, Hasson H, Bossolasco S, **Lazzarin A**, Tambussi G, Castagna A. *J Acquir Immune Defic Syndr*. 2012 Jul 1;60(3):e101-3. doi: 10.1097/QAI.0b013e318258bf3c.PMID: 22728751 No abstract available.

324

Cite

Share

[Detection of \*Pneumocystis carinii\* and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.](#)

Zingale A, Carrera P, **Lazzarin A**, Scarpellini P. *J Clin Microbiol*. 2003 Jun;41(6):2709-12. doi: 10.1128/JCM.41.6.2709-2712.2003.PMID: 12791912 **Free PMC article.**

325

Cite

Share

[Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.](#)

Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, **Lazzarin A**. *J Med Virol*. 2004 Feb;72(2):181-6. doi: 10.1002/jmv.10580.PMID: 14695657

326

Cite

Share

[Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.](#)

Seminari E, Guffanti M, Villani P, Gianotti N, Cusato M, Fusetti G, Galli A, Castagna A, Regazzi M, **Lazzarin A**. *Eur J Clin Pharmacol*. 2005 Aug;61(7):545-9. doi: 10.1007/s00228-005-0966-x. Epub 2005 Jul 23. PMID: 16041598

327

Cite

Share

[Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.](#)

Gianotti N, Maillard M, Gaiera G, Bestetti A, Cernuschi M, De Bona A, **Lazzarin A**, Cinque P, Bossolasco S. *New Microbiol*. 2008 Jul;31(3):435-8. PMID: 18843901 **Free article.**

328

Cite

Share

[The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.](#)

Giordano M, Kelleher T, Colonna RJ, **Lazzarin A**, Squires K. *J Clin Virol*. 2006 Apr;35(4):420-5. doi: 10.1016/j.jcv.2005.10.011. PMID: 16604577

329

Cite

Share

[Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.](#)

Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, **Lazzarin A**, Castagna A.J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.PMID: 24458511 No abstract available.

330

Cite

Share

[Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection.](#)

Nozza S, Pignataro AR, Galli L, Ripa M, Boeri E, Chiappetta S, Galli A, Canducci F, Sampaolo M, Clementi M, **Lazzarin A**, Tambussi G.J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e27-9. doi: 10.1097/QAI.0b013e3182a03ed2.PMID: 24419069 No abstract available.

331

Cite

Share

[Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.](#)

Calcagno A, Nozza S, Gonzalez de Requena D, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, **Lazzarin A**, Bonora S.J Antimicrob Chemother. 2013 Jul;68(7):1686-8. doi: 10.1093/jac/dkt074. Epub 2013 Mar 14.PMID: 23493315 No abstract available.

332

Cite

Share

[Pretreatment of chronic active hepatitis C in patients coinfectd with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.](#)

Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, **Lazzarin A**.J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):146-52. doi: 10.1097/00126334-200306010-00005.PMID: 12794546 Clinical Trial.

333

Cite

Share

[Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment.](#)

Spagnuolo V, Cocorullo D, Galli L, Bigoloni A, Galli A, Rubinacci A, Mignogna G, Carbone A, **Lazzarin A**, Castagna A.J Antimicrob Chemother. 2013 Dec;68(12):2960-3. doi: 10.1093/jac/dkt264. Epub 2013 Jun 27.PMID: 23812682 No abstract available.

334

Cite

Share

[Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.](#)

Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B, Canducci F, Clementi M, **Lazzarin A**, Castagna A.J Antimicrob Chemother. 2012 Jan;67(1):213-7. doi: 10.1093/jac/dkr422. Epub 2011 Oct 10.PMID: 21987242

335

Cite

Share

[Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study.](#)

Spagnuolo V, Galli L, Bigoloni A, Nozza S, Monforte Ad, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, **Lazzarin A**, Castagna A.J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19806. doi: 10.7448/IAS.17.4.19806. eCollection 2014.PMID: 25397550 **Free PMC article.**

336

Cite

Share

[Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.](#)

Hasson H, Gianotti N, Danise A, Seminari E, Boeri E, Nozza S, Castagna A, **Lazzarin A**. *AIDS*. 2004 Jan 2;18(1):123-7. doi: 10.1097/00002030-200401020-00016.PMID: 15090838

337

Cite

Share

[Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.](#)

Burighel N, Ghezzi S, Nozza S, Del Bianco P, **Lazzarin A**, Tambussi G, Poli G, De Rossi A. *Haematologica*. 2006 Feb;91(2):244-7.PMID: 16461311 Clinical Trial.

338

Cite

Share

[Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.](#)

Gathe JC Jr, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, **Lazzarin A**, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D. *AIDS Res Hum Retroviruses*. 2007 Feb;23(2):216-23. doi: 10.1089/aid.2006.0178.PMID: 17263650 Clinical Trial.

339

Cite

Share

[Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance.](#)

Bestetti A, Presi S, Pierotti C, Bossolasco S, Sala S, Racca S, Carrera P, **Lazzarin A**, Cinque P. *J Neurovirol*. 2004;10 Suppl 1:52-7. doi: 10.1080/753312753.PMID: 14982740

340

Cite

Share

[Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration.](#)

Porcellini S, Vallanti G, Nozza S, Poli G, **Lazzarin A**, Tambussi G, Siccardi AG, Grassi F. *AIDS*. 2003 Jul 25;17(11):1621-30. doi: 10.1097/00002030-200307250-00006.PMID: 12853744 Clinical Trial.

341

Cite

Share

[In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders.](#)

Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, **Lazzarin A**, Beretta A. *Clin Immunol*. 2003 Dec;109(3):355-8. doi: 10.1016/j.clim.2003.07.001.PMID: 14697751 Clinical Trial.

342

Cite

Share

[Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome.](#)

Gianotti N, Soria A, Galli L, Giudici B, Fusetti G, **Lazzarin A**, Boeri E, Castagna A. *AIDS*. 2004 Mar 26;18(5):821-3. doi: 10.1097/00002030-200403260-00018.PMID: 15075522 No abstract available.

343

Cite

Share

[Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.](#)

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnotou R, Buard V, Kfutwah A, Vessièrè A, Rousset D, Teck R, Calmy A, Ciaffi L, **Lazzarin A**, Gianotti N. *Antivir Ther*. 2009;14(3):339-47.PMID: 19474468



344

Cite

Share

[Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.](#)

Cossarini F, Galli L, Sagnelli C, Gianotti N, Hasson H, Clementi M, Soria A, Salpietro S, **Lazzarin A**, Castagna A. *J Acquir Immune Defic Syndr*. 2009 Jun 1;51(2):179-84. doi: 10.1097/QAI.0b013e3181a56f46.PMID: 19352200

345

Cite

Share

[Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.](#)

Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, **Lazzarin A**, Clementi M. *Antimicrob Agents Chemother*. 2004 Sep;48(9):3253-9. doi: 10.1128/AAC.48.9.3253-3259.2004.PMID: 15328081 **Free PMC article.**

346

Cite

Share

[The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.](#)

Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, **Lazzarin A**. *Antivir Ther*. 2004 Aug;9(4):537-43.PMID: 15456085 *Clinical Trial*.

347

Cite

Share

[Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.](#)

Gianotti N, Seminari E, **Lazzarin A**, Boeri E, Clementi M, Danise A, Salpietro S, Fusetti G, Castagna A. *AIDS Res Hum Retroviruses*. 2005 Jun;21(6):545-54. doi: 10.1089/aid.2005.21.545.PMID: 15989459 Clinical Trial.

348

Cite

Share

[Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.](#)

Boeri E, Gianotti N, Canducci F, Hasson H, Giudici B, Castagna A, **Lazzarin A**, Clementi M. *AIDS Res Hum Retroviruses*. 2003 Dec;19(12):1151-3. doi: 10.1089/088922203771881257.PMID: 14714567

349

Cite

Share

[Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.](#)

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, **Lazzarin A**, Castagna A. *New Microbiol*. 2005 Apr;28(2):119-25.PMID: 16035256 Clinical Trial.

350

Cite

Share

[Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.](#)

Hasson H, Biswas P, Galli L, Burastero SE, Danise A, Bigoloni A, Carini E, Locatelli M, Vecchi A, **Lazzarin A**, Castagna A. *New Microbiol*. 2006 Oct;29(4):223-30.PMID: 17201088

351

Cite

Share

[Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients.](#)

Turriziani O, Gianotti N, Bambacioni F, Manconi PE, **Lazzarin A**, Antonelli G. *AIDS Res Hum Retroviruses*. 2004 Jul;20(7):701-3. doi: 10.1089/0889222041524553.PMID: 15307913

352

Cite

Share

[In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.](#)

Gianotti N, Galli L, Boeri E, Maillard M, Serra G, Ratti D, Gallotta G, Vacchini D, Tremolada Y, **Lazzarin A**, Clementi M, Castagna A. *New Microbiol*. 2005 Oct;28(4):319-26.PMID: 16386016

353

Cite

Share

[Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.](#)

Malnati M, Broccolo F, Nozza S, Sarmati L, Ghezzi S, Locatelli G, Delfanti F, Capiluppi B, Careddu A, Andreoni M, Monini P, Poli G, **Lazzarin A**, Lusso P, Tambussi G. *Blood*. 2002 Sep 1;100(5):1575-8.PMID: 12176873 **Free article.**

354

Cite

Share

[The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.](#)

Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, **Lazzarin A**, Castagna A. *J Acquir Immune Defic Syndr*. 2006 Apr 1;41(4):447-52. doi: 10.1097/01.qai.0000209903.89878.80.PMID: 16652052

□ 355

Cite

Share

[Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine.](#)

Sudre P, Chave JP, Ruef C, Iten A, Bucher HC, Vernazza PL, Furrer H, Bernasconi E, Ceserani N, Battegay M, Von Overbeck J, Cassis I, **Lazzarin A**, Gabriel V, Hirschel BJ; The Swiss HIV Cohort Study. *Clin Microbiol Infect.* 1997 Feb;3(6):629-633. doi: 10.1111/j.1469-0691.1997.tb00469.x.PMID: 11864204 **Free article.**